Guided Therapeutics (GTHP) 10-Q 11 Feb 20 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Feb. 07, 2020
Document And Entity Information
Entity Registrant Name	GUIDED THERAPEUTICS INC
Entity Central Index Key	0000924515
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,319,486
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents	$ 0	$ 0
Accounts receivable, net of allowance for doubtful accounts of $157 at June 30, 2019 and December 31, 2018, respectively	16	13
Inventory, net of reserves of $831and $767, at June 30, 2019 and December 31, 2018, respectively	48	114
Other current assets	2	69
Total current assets	66	196
Property and equipment, net	0	21
Lease asset-right, net of amortization	175	0
Other assets	19	19
Total noncurrent assets	194	40
TOTAL ASSETS	260	236
CURRENT LIABILITIES:
Notes payable in default, related parties	349	334
Notes payable in default	366	366
Short-term notes payable	313	225
Short-term notes payable, related parties	551	674
Convertible notes in default	2,882	2,778
Short-term convertible notes payable, related parties	468	380
Short-term convertible notes payable	52	0
Accounts payable	2,924	3,013
Accounts payable, related parties	118	0
Accrued liabilities	3,518	3,156
Current portion of lease liability	103	0
Customer deposits	99	66
Total current liabilities	11,743	10,992
LONG-TERM LIABILITIES:
Warrants, at fair value	6,478	4,728
Lease liability	72	0
Long-term debt-related parties	552	340
Total long-term debt	7,102	5,068
TOTAL LIABILITIES	18,845	16,060
COMMITMENTS & CONTINGENCIES (Note 7)
STOCKHOLDERS' DEFICIT:
Common stock, $.001 Par value; 3,000,000 shares authorized, 3,319 and 2,669 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively	3,393	2,877
Additional paid-in capital	117,860	118,259
Treasury stock, at cost	(132)	(132)
Accumulated deficit	(140,512)	(137,634)
TOTAL STOCKHOLDERS' DEFICIT	(18,585)	(15,824)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	260	236
Series C Convertible Preferred Stock
STOCKHOLDERS' DEFICIT:
Convertible preferred stock	105	105
Series C-1 Convertible Preferred Stock
STOCKHOLDERS' DEFICIT:
Convertible preferred stock	170	170
Series C-2 Convertible Preferred Stock
STOCKHOLDERS' DEFICIT:
Convertible preferred stock	$ 531	$ 531

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
CURRENT ASSETS
Accounts receivable, net of allowance	$ 157	$ 157
Inventory, net of reserves	$ 831	$ 767
STOCKHOLDERS' DEFICIT:
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	1,000,000	1,000,000
Common stock, issued	3,319	2,669
Common stock, outstanding	3,319	2,669
Series C Convertible Preferred Stock
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ .001	$ 0.001
Preferred stock, authorized	9	9
Preferred stock, issued	0.3	0.3
Preferred stock, outstanding	0.3	0.3
Preferred stock, liquidation preference	$ 286	$ 286
Series C-1 Convertible Preferred Stock
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ .001	$ .001
Preferred stock, authorized	20.3	20.3
Preferred stock, issued	1	1
Preferred stock, outstanding	1	1
Preferred stock, liquidation preference	$ 1,049	$ 1,049
Series C-2 Convertible Preferred Stock
STOCKHOLDERS' DEFICIT:
Preferred stock, par value	$ .001	$ 0.001
Preferred stock, authorized	5,000	5,000
Preferred stock, issued	3.3	3.3
Preferred stock, outstanding	3.3	3.3
Preferred stock, liquidation preference	$ 3,263	$ 3,263

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
REVENUE:
Sales - devices and disposables	$ 1	$ 8	$ 19	$ 13
Cost of goods sold	65	1	66	3
Gross (loss) profit	(64)	7	(47)	10
OPERATING EXPENSES:
Research and development	43	62	90	132
Sales and marketing	31	55	76	117
General and administrative	189	381	371	626
Total operating expenses	263	498	537	875
Operating loss	(327)	(491)	(584)	(865)
OTHER INCOME (EXPENSES):
Other income	16	9	19	36
Interest expense	(264)	(296)	(634)	(556)
Changes in fair value of warrants	(2,088)	4,198	(1,679)	5,886
Total other (expenses) income	(2,336)	3,911	(2,294)	5,366
(LOSS) INCOME BEFORE INCOME TAXES	(2,663)	3,420	(2,878)	4,501
PROVISION FOR INCOME TAXES	0	0	0	0
NET (LOSS) INCOME	(2,663)	3,420	(2,878)	4,501
PREFERRED STOCK DIVIDENDS	9	(42)	0	(97)
NET (LOSS) INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (2,654)	$ 3,378	$ (2,878)	$ 4,404
NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS, BASIC	$ (0.81)	$ 13.73	$ (0.87)	$ 24.6
NET (LOSS) INCOME PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS, DILUTED	$ (0.81)	$ 1.24	$ (0.87)	$ 1.47
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, BASIC	3,284	246	3,319	179
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING, DILUTED	3,284	2,716	3,319	2,999

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ (2,878)	$ 4,501
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Bad debt (recovery) expense	0	1
Depreciation	21	17
Amortization of debt issuance costs and discounts	46	96
Amortization of beneficial conversion feature	54	0
Share-based compensation	8	27
Change in fair value of warrants	1,679	(5,886)
Changes in operating assets and liabilities:
Inventory	66	(14)
Accounts receivable	(3)	(3)
Other current assets	67	69
Other assets	0	42
Accounts payable	29	(60)
Deferred revenue	33	(4)
Accrued liabilities	504	577
Total adjustments	2,558	(5,138)
Net cash used in operating activities	(374)	(637)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from debt financing, net of discounts and debt issuance costs	474	707
Payments made on notes payable	(100)	(114)
Proceeds for future issuance of common stock	0	84
Net cash provided by financing activities	374	677
NET CHANGE IN CASH AND CASH EQUIVALENTS	0	40
CASH AND CASH EQUIVALENTS, beginning of year	0	1
CASH AND CASH EQUIVALENTS, end of period	0	41
SUPPLEMENTAL SCHEDULE OF:
Cash paid for: Interest	0	115
NONCASH INVESTING AND FINANCING ACTIVITIES:
Issuance of common stock as debt repayment	33	463
Dividends on preferred stock	$ 0	$ 97

1. ORGANIZATION, BACKGROUND, AN

1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION	Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers. Basis of Presentation All information and footnote disclosures included in the consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. A 1:800 reverse stock split of all of the Company’s issued and outstanding common stock was implemented on March 29, 2019. As a result of the reverse stock split, every 800 shares of issued and outstanding common stock were converted into 1 share of common stock. All fractional shares created by the reverse stock split were rounded to the nearest whole share. The number of authorized shares of common stock did not change. The reverse stock split decreased the Company’s issued and outstanding shares of common stock from 2,652,309,322 shares to 3,319,486 shares as of that date with rounding. See Note 4, Stockholders’ Deficit. Unless otherwise specified, all per share amounts are reported on a post-stock split basis, as of June 30, 2019. The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of June 30, 2019, it had an accumulated deficit of approximately $140.6 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development. Certain prior year amounts have been reclassified in order to conform to the current year presentation. Going Concern The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. At June 30, 2019, the Company had a negative working capital of approximately $11.6 million, accumulated deficit of $140.5 million, and incurred a net loss of $2.9 million for the six months then ended. Stockholders’ deficit totaled approximately $18.6 million at June 30, 2019, primarily due to recurring net losses from operations, deemed dividends on warrants and preferred stock, offset by proceeds from the exercise of options and warrants and proceeds from sales of stock. The Company’s capital-raising efforts are ongoing and the Company has taken the following steps to increase the likelihood of a successful financing: 1) Debt will be significantly reduced and additional agreements will be executed, contingent on a successful financing, to reduce debt even further either by forgiveness of debt and/or exchanges of debt for equity 2) Monthly operating expenses have been reduced by nearly 50% since the beginning of 2017 and 3) Variable rate loans for the most part have either been paid off or converted to equity. If sufficient capital cannot be raised during 2020, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection. The Company had warrants exercisable for approximately 38.2 million shares of its common stock outstanding at June 30, 2019 with exercise prices ranging between $0.04 and $29.5 million per share. The Company estimates that only a portion of these warrants would be exercisable given the high exercise prices and would generate a total of approximately $3.0 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the public or private sale of debt or equity, and grants, if available. However, please refer to Footnote 10 - CONVERTIBLE DEBT IN DEFAULT in the paragraph: Debt Restructuring for more information regarding our warrants.

2. SIGNIFICANT ACCOUNTING POLIC

2. SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
2. SIGNIFICANT ACCOUNTING POLICIES	The Company’s significant accounting policies were set forth in the audited financial statements and notes thereto for the year ended December 31, 2018 included in its annual report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”). Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants. Principles of Consolidation The accompanying consolidated financial statements include the accounts of Guided Therapeutics, Inc. and its wholly owned subsidiary. All intercompany transactions are eliminated. Accounting Standard Updates Implemented In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” that requires lessees to recognize on the balance sheet the assets and liabilities associated with the rights and obligations created by those leases. Under the new guidance, a lessee is required to recognize assets and liabilities for leases with lease terms of more than 12 months. Consistent with current U.S. GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily depends on its classification as finance or operating lease. The update is effective for reporting periods beginning after December 15, 2018. The a Except as noted above, the guidance issued by the FASB during the current year is not expected to have a material effect on the Company’s consolidated financial statements. A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company’s consolidated financial statements. Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent. Accounts Receivable The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. The Company does not accrue interest receivable on past due accounts receivable. Concentrations of Credit Risk The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk. Inventory Valuation All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. At June 30, 2019 and December 31, 2018, our inventories were as follows (in thousands): June 30, December 31, 2019 2018 Raw materials $ 781 $ 783 Work in process 81 81 Finished goods 17 17 Inventory reserve (831 ) (767 ) Total $ 48 $ 114 The Company maintains reserves for excess and obsolete inventories to reflect inventory at . The Company’s estimate for excess and obsolete inventory is based upon the assumptions about future demand and market conditions. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company was able to sell such inventory any related reserves would be reversed in the period of sale. Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the consolidated statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at June 30, 2019 and December 31, 2018 (in thousands): June 30, December 31, 2019 2018 Equipment $ 1,349 $ 1,378 Software 740 740 Furniture and fixtures 124 124 Leasehold Improvement 180 199 2,393 2,441 Less accumulated depreciation and amortization (2,393 ) (2,420 ) Total $ — $ 21 Debt Issuance Costs Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the consolidated balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount. Other Assets Other assets primarily consist of a deposit for the corporate office. Patent Costs (Principally Legal Fees) Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs aggregated approximately $10,000 and $7,000 for the six months ended June 30, 2019 and 2018, respectively. Leases With the implementation of ASU 2016-02, “Leases (Topic 842)”, the Company recorded a lease asset-right and a lease liability. The implementation required the analysis of certain criteria in determining its treatment. The Company determined that its corporate office lease met those criteria. The Company implemented the guidance using the alternative transition method. Under this alternative, the effective date would be the date of initial application. The Company analyzed the lease at its effective date and calculated an initial lease payment amount of $267,380 with a present value of $213,000 using a 20% discount. As of June 30, 2019, the balance of the lease asset – right and lease liability was approximately $175,000. Rent was unpaid as of June 30, 2019, and therefore the Company is including rent in accounts payable. The cumulative effect of initially applying the new guidance had an immaterial impact on the opening balance of retained earnings, The Company does not expect the guidance to have a material impact on its consolidated net earnings in future periods. The Company elected the Practical expedients permitted under the transition guidance within the new standards, which allowed the Company to carry forward the historical lease classification. Accrued Liabilities Accrued liabilities are summarized as follows (in thousands): June 30, 2019 December 31, 2018 Compensation $ 1,046 $ 1,030 Professional fees 175 203 Interest 1,241 892 Warranty 2 2 Vacation 50 53 Preferred dividends 120 120 Stock subscription for licenses 692 692 Other accrued expenses 192 164 Total $ 3,518 $ 3,156 Revenue Recognition The Company follows, ASC 606 Revenue from Contracts with Customers establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, Revenue based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and, the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. Revenue by product line (in thousands): Six Months Ended June 30, 2019 2018 Devices $ — $ — Disposables 2 8 Other 15 1 Warranty 2 4 Total $ 19 $ 13 Revenue by geographic location (in thousands): Six Months Ended June 30, 2019 2018 Asia $ 5 $ — Africa — 9 Europe 14 4 North America — — South America — — Total $ 19 $ 13 Significant Distributors During the six months ended June 30, 2019, all the Company’s revenues were from two distributors and for extended warranties. Revenue from these distributors totaled approximately $19,000 for the period ended June 30, 2019. Accounts receivable were from one distributor and represents 100% of the balance for the period ended June 30, 2019. During the six months ended June 30, 2018, revenues were from three distributors, that totaled approximately $13,000. Deferred revenue The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of June 30, 2019, and December 31, 2018, the Company did not have deferred revenue, respectively. Customer deposits The Company follows the same principal as explained in Revenue Recognition and ASC 606. As of June 30, 2019, and December 31, 2018, the Company has received prepayments for devices and disposables and recorded this as customer deposits in the amount of $99,000 and $66,000, respectively. Research and Development Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred. Income Taxes The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management provides valuation allowances against the deferred tax assets for amounts that are not considered more likely than not to be realized. The Company is currently delinquent with its federal and applicable state tax return filings, payments and certain Federal and State Unemployment Tax filings. Some of the federal income tax returns are currently under examination by the U.S. Internal Revenue Service (“IRS”). The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company is currently in process of setting up a payment arrangement for its delinquent state income taxes with the State of Georgia and the returns are currently under review by state authorities. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At December 31, 2018, the Company has approximately $77.2 million of net operating losses. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. Corporate tax rates in the U.S. have decreased from 34% to 21%. Uncertain Tax Positions The Company assesses each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. At June 30, 2019 and December 31, 2018, there were no uncertain tax positions. Warrants The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants issued to non-employees based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model. Stock Based Compensation The Company records compensation expense related to options granted to employees and non-employees based on the fair value of the award. Compensation cost is recorded as earned for all unvested stock options outstanding at the beginning of the first year based upon the grant date fair value estimates, and for compensation cost for all share-based payments granted or modified subsequently based on fair value estimates. For the six months ended June 30, 2019 and 2018 share-based compensation for options attributable to employees, non-employees, officers and Board members were approximately $8,000 and $27,000. These amounts have been included in the Company’s statements of operations. Compensation costs for stock options which vest over time are recognized over the vesting period. As of June 30, 2019, the Company did not have any unrecognized compensation costs related to granted stock options that will be recognized. Beneficial Conversion Features of Convertible Securities Conversion options that are not bifurcated as a derivative pursuant to ASC 815 and not accounted for as a separate equity component under the cash conversion guidance are evaluated to determine whether they are beneficial to the investor at inception (a beneficial conversion feature) or may become beneficial in the future due to potential adjustments. The beneficial conversion feature guidance in ASC 470-20 applies to convertible stock as well as convertible debt which are outside the scope of ASC 815. A beneficial conversion feature is defined as a nondetachable conversion feature that is in the money at the commitment date. The beneficial conversion feature guidance requires recognition of the conversion option’s in-the-money portion, the intrinsic value of the option, in equity, with an offsetting reduction to the carrying amount of the instrument. The resulting discount is amortized as a dividend over either the life of the instrument, if a stated maturity date exists, or to the earliest conversion date, if there is no stated maturity date. If the earliest conversion date is immediately upon issuance, the dividend must be recognized at inception. When there is a subsequent change to the conversion ratio based on a future occurrence, the new conversion price may trigger the recognition of an additional beneficial conversion feature on occurrence. Derivatives The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.

3. FAIR VALUE OF FINANCIAL INST

3. FAIR VALUE OF FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
3. FAIR VALUE OF FINANCIAL INSTRUMENTS	The guidance for fair value measurements, ASC 820, Fair Value Measurements and Disclosures, establishes the authoritative definition of fair value, sets out a framework for measuring fair value, and outlines the required disclosures regarding fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy based upon observable and non-observable inputs as follow: · Level 1 – Quoted market prices in active markets for identical assets and liabilities; · Level 2 – Inputs, other than level 1 inputs, either directly or indirectly observable; and · Level 3 – Unobservable inputs developed using internal estimates and assumptions (there is little or no market date) which reflect those that market participants would use. The Company records its derivative activities at fair value, which consisted of warrants as of June 30, 2019. The fair value of the warrants was estimated using the Binomial Simulation model. Gains and losses from derivative contracts are included in net gain (loss) from derivative contracts in the statement of operations. The fair value of the Company’s derivative warrants is classified as a Level 3 measurement, since unobservable inputs are used in the valuation. The following table presents the fair value for those liabilities measured on a recurring basis as of June 30, 2019 and December 31, 2018: FAIR VALUE MEASUREMENTS (In Thousands) The following is summary of items that the Company measures at fair value on a recurring basis: Fair Value at June 30, 2019 Level 1 Level 2 Level 3 Total Warrants issued in connection with Distributor Debt $ — $ — $ (114 ) $ (114 ) Warrants issued in connection with Senior Secured Debt (6,293 ) (6,293 ) Warrants issued in connection with Short-Term Loans — — (71 ) (71 ) Total long-term liabilities at fair value $ — $ — $ (6,478 ) $ (6,478 ) Fair Value at December 31, 2018 Level 1 Level 2 Level 3 Total Warrants issued in connection with Distributor Debt $ — $ — $ (114 ) $ (114 ) Warrants issued in connection with Senior Secured Debt — — (4,614 ) (4,614 ) Total long-term liabilities at fair value $ — $ — $ (4,728 ) $ (4,728 ) The following is a summary of changes to Level 3 instruments during the six months ended June 30, 2019: Distributor Debt Short-Term Loans Senior Secured Debt Total Balance, December 31, 2018 $ (114 ) $ — $ (4,614 ) $ (4,728 ) Warrants issued during the period — (71 ) — (71 ) Change in fair value during the period — — (1,679 ) (1,679 ) Balance, June 30, 2019 $ (114 ) $ (71 ) $ (6,293 ) $ (6,478 ) As of June 30, 2019, the fair value of warrants was approximately $6.5 million. A net change of approximately $1.7 million has been recorded to the accompanying consolidated statement of operations for the six months ended June 30, 2019.

4. STOCKHOLDERS' DEFICIT

4. STOCKHOLDERS' DEFICIT	6 Months Ended
	Jun. 30, 2019
STOCKHOLDERS' DEFICIT:
4. STOCKHOLDERS' DEFICIT	Common Stock The Company has authorized 3,000,000,000 shares of common stock with $0.001 par value, of which 3,319,486 were issued and outstanding as of June 30, 2019. As of December 31, 2018, there were 3,000,000,000 authorized shares of common stock, of which 2,669,348 were issued and outstanding. For the six months ended June 30, 2019, the Company issued 650,138 shares of common stock as listed below: Convertible Debt Conversions 650,138 Summary table of common stock share transactions: Balance at December 31, 2018 2,669,348 Issued in 2019 650,138 Balance at June 30, 2019 3,319,486 On January 22, 2017, the Company entered into a license agreement with Shandong Yaohua Medical Instrument Corporation, or SMI, pursuant to which the Company granted SMI an exclusive global license to manufacture the LuViva device and related disposables (subject to a carve-out for manufacture in Turkey) and exclusive distribution rights in the Peoples Republic of China, Macau, Hong Kong and Taiwan. In exchange for the license, SMI will pay a $1.0 million licensing fee, payable in five installments through November 2017, as well as a royalty on each disposable sold in the territories. As of June 30, 2019, SMI had paid $750,000. SMI will also underwrite the cost of securing approval of LuViva with the Chinese Food and Drug Administration, or CFDA. Pursuant to the SMI agreement, SMI must become capable of manufacturing LuViva in accordance with ISO 13485 for medical devices by the second anniversary of the SMI agreement, which would have caused the forfeiture of the license. The Company has granted an extension of the forfeiture expiration date and is currently negotiating the terms with SMI. Based on the agreement, SMI must purchase no fewer than ten devices (with up to two devices pushed to 2018 if there is a delay in obtaining approval from the CFDA). SMI purchased five devices in 2017 and have not purchased any in 2018. In the three years following CFDA approval, SMI must purchase a minimum of 3,500 devices (500 in the first year, 1,000 in the second, and 2,000 in the third) or else forfeit the license. As manufacturer of the devices and disposables, SMI will be obligated to sell each to us at costs no higher than our current costs. As partial consideration for, and as a condition to, the license, and to further align the strategic interests of the parties, the Company agreed to issue $1.0 million in shares of its common stock to SMI, in five installments through October 2017, at a price per share equal to the lesser of the average closing price for the five days prior to issuance or $1.25. These shares have not been issued as of June 30, 2019. In order to facilitate the SMI agreement, immediately prior to its execution the Company entered into an agreement with Shenghuo Medical, LLC, regarding its previous license to Shenghuo (see Note 7, Commitments and Contingencies). Under the terms of the new agreement, Shenghuo agreed to relinquish its manufacturing license and its distribution rights in SMI’s territories, and to waive its rights under the original Shenghuo agreement, all for as long as SMI performs under the SMI agreement. As consideration, the Company agreed to split with Shenghuo the licensing fees and net royalties from SMI that the Company will receive under the SMI agreement. Should the SMI agreement be terminated, the Company have agreed to re-issue the original license to Shenghuo under the original terms. The Company’s COO and director, Mark Faupel, is a shareholder of Shenghuo, and a former director, Richard Blumberg, is a managing member of Shenghuo. During 2018, the Company had exercised its rights under the $10,000,000 GHS Equity Financing Agreement entered into on March 1, 2018, to exercise puts of $47,320 for the issuance of 87,500 common stock shares. Pursuant to the agreement a put maybe executed for a price that is 80% of the “market price” which is the average of the two lowest volume weighted average prices of the Company’s common stock for 15 consecutive trading days preceding the put date. Preferred Stock The Company has authorized 5,000,000 shares of preferred stock with a $.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. The board of directors designated 525,000 shares of preferred stock redeemable convertible preferred stock, none of which remain outstanding, 33,000 shares of preferred stock as Series B Preferred Stock, none of which remain outstanding, 9,000 shares of preferred stock as Series C Convertible Preferred Stock, (the “Series C Preferred Stock”), of which 286 were issued and outstanding at June 30, 2019 and December 31, 2018, respectively and 20,250 shares of preferred stock as Series C1 Preferred Stock, of which 1,050 shares were issued and outstanding at June 30, 2019 and December 31, 2018, respectively. On August 31, 2018, the Company entered into agreements with certain holders of the Company’s Series C1 Preferred Stock, including the chairman of the Company’s board of directors, and the Chief Operating Officer and a director of the Company (the “Exchange Agreements”), pursuant to which those holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 preferred stock, par value $0.001 per share (the “Series C2 Preferred Stock”). In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. Series C Convertible Preferred Stock On June 29, 2015, the Company entered into a securities purchase agreement with certain accredited investors, including John Imhoff and Mark Faupel, members of the Board, for the issuance, exchange and sale of an aggregate of 6,737 shares of Series C convertible preferred stock, at a purchase price of $750 per share and a stated value of $1,000 per share. Additionally, during October 2015 the Company entered into an interim agreement amending the securities purchase agreement to provide for certain of the investors to purchase an additional aggregate of 1,166 shares. For a total of Series C convertible preferred stock issued of 7,903 shares. Of the 7,903 Series C convertible preferred stock issued, 1,835 were issued in exchange of Series B convertible preferred stock. Therefore 6,068 Series C preferred stock were issued at a purchase price of $750 for gross proceeds of $4,551,000. The Company received net cash proceeds of $3,698,000, after cash and non-cash expenses of $853,000. Pursuant to the Series C certificate of designations, shares of Series C preferred stock are convertible into common stock by their holder at any time and may be mandatorily convertible upon the achievement of specified average trading prices for the Company’s common stock. At June 30, 2019, there were 286 shares outstanding with a conversion price of $2.099 per share, such that each share of Series C preferred stock would convert into approximately 476 shares of the Company’s common stock, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Series C certificate of designations. The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt. Holders of the Series C preferred stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, the Company’s common stock. In addition, upon conversion of the Series C preferred stock prior to the Dividend End Date, the Company will also pay to the converting holder a “make-whole payment” equal to the number of unpaid dividends through the Dividend End Date on the converted shares. At June 30, 2019, the “make-whole payment” for a converted share of Series C preferred stock would convert to 200 shares of the Company’s common stock. The Series C preferred stock generally has no voting rights except as required by Delaware law. Upon the Company’s liquidation or sale to or merger with another corporation, each share will be entitled to a liquidation preference of $1,000, plus any accrued but unpaid dividends. In addition, the purchasers of the Series C preferred stock received, on a pro rata basis, warrants exercisable to purchase an aggregate of approximately 1 share of Company’s common stock. The warrants contain anti-dilution adjustments in the event that the Company issues shares of common stock, or securities exercisable or convertible into shares of common stock, at prices below the exercise price of such warrants. As a result of the anti-dilution protection, the Company is required to account for the warrants as a liability recorded at fair value each reporting period. At June 30, 2019, the exercise price per share was $512,000. On May 23, 2016, an investor canceled certain of these warrants, exercisable into 903 shares of common stock. The same investor also transferred certain of these warrants, exercisable for 150 shares of common stock, to two investors who also had participated in the 2015 Series C financing. Series C1 Convertible Preferred Stock Between April 27, 2016 and May 3, 2016, the Company entered into various agreements with certain holders of Series C preferred stock, including directors John Imhoff and Mark Faupel, pursuant to which those holders separately agreed to exchange each share of Series C preferred stock held for 2.25 shares of the Company’s newly created Series C1 Preferred Stock and 12 (9,600 pre-split) shares of the Company’s common stock (the “Series C Exchanges”). In connection with the Series C Exchanges, each holder also agreed to roll over the $1,000 stated value per share of the holder’s shares of Series C1 Preferred Stock into the next qualifying financing undertaken by the Company on a dollar-for-dollar basis and, except in the event of an additional $50,000 cash investment in the Company by the holder, to execute a customary “lockup” agreement in connection with the financing. In total, for 1,916 shares of Series C preferred stock surrendered, the Company issued 4,312 shares of Series C1 Preferred Stock and 29 shares of common stock. At June 30, 2019, there were 1,050 shares outstanding with a conversion price of $2.099 per share, such that each share of Series C preferred stock would convert into approximately 476 shares of the Company’s common stock. On August 31, 2018, 3,262.25 shares of Series C1 Preferred Stock were surrendered, and the Company issued 3,262.25 shares of Series C2 Preferred Stock. At June 30, 2019, shares of Series C2 had a conversion price of $2.099 per share, such that each share of Series C preferred stock would convert into approximately 476 shares of the Company’s common stock. The Series C1 preferred stock has terms that are substantially the same as the Series C preferred stock, except that the Series C1 preferred stock does not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C preferred stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt. Series C2 Convertible Preferred Stock On August 31, 2018, the Company entered into agreements with certain holders of the Company’s Series C1 Preferred Stock, including the chairman of the Company’s board of directors, and the Chief Operating Officer and a director of the Company pursuant to which those holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. The terms of the Series C2 Preferred Stock are substantially the same as the Series C1 Preferred Stock, except that (i) shares of Series C1 Preferred Stock may not be convertible into the Company’s common stock by their holder for a period of 180 days following the date of the filing of the Certificate of Designation (the “Lock-Up Period”); (ii) the Series C2 Preferred Stock has the right to vote as a single class with the Company’s common stock on an as-converted basis, notwithstanding the Lock-Up Period; and (iii) the Series C2 Preferred Stock will automatically convert into that number of securities sold in the next Qualified Financing (as defined in the Exchange Agreement) determined by dividing the stated value ($1,000 per share) of such share of Series C2 Preferred Stock by the purchase price of the securities sold in the Qualified Financing. Warrants The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the six months ended June 30, 2019: Warrants (Underlying Shares) Outstanding, January 1, 2019 23,551,857 Issuances 14,650,000 Canceled / Expired (10 ) Exercised - Outstanding, June 30, 2019 38,201,847 The Company had the following shares reserved for the warrants as of June 30, 2019: Warrants Exercise Price Expiration Date 13 (1) $60,000.00 per share June 14, 2021 3 (4) $24,320,000.00 per share September 10, 2019 1 (5) $29,491,840.00 per share September 27, 2019 4 (6) $18,003,200.00 per share December 2, 2019 2 (7) $5,760,000.00 per share December 2, 2020 2 (8) $7,040,000.00 per share December 2, 2020 1 (9) $7,603,200.00 per share June 29, 2020 13 (9) $512,000.00 per share September 21, 2020 24 (10) $512,000.00 per share June 29, 2020 12 (11) $512,000.00 per share September 4, 2020 1 (12) $7,603,200.00 per share September 4, 2020 1 (13) $512,000.00 per share October 23, 2020 1 (14) $7,603,200.00 per share October 23, 2020 35,937,500 (15) $0.04 per share June 14, 2021 1,725,000 (16) $0.04 per share February 21, 2021 22 (17) $11,137.28 per share June 6, 2021 250 (18) $0.04 per share February 13, 2022 25 (19) $144.00 per share May 16, 2022 688 (20) $15.20 per share November 16, 2020 250 (21) $15.20 per share December 28, 2020 75 (22) $16.08 per share January 10, 2021 4,262 (23) $0.04 per share March 19, 2021 1,875 (24) $16.08 per share March 20, 2021 63 (25) $48.00 per share April 30, 2021 125 (26) $48.00 per share May 17, 2021 125 (27) $48.00 per share May 25, 2021 500 (28) $48.00 per share June 1, 2021 1,875 (29) $200.00 per share August 22, 2021 625 (30) $200.00 per share September 18, 2021 1,250 (31) $1.12 per share October 23, 2021 19 (32) $0.64 per share November 20, 2021 375 (33) $0.32 per share December 5, 2021 100 (34) $0.16 per share December 19, 2021 188 (35) $0.24 per share December 23, 2021 14 (36) $0.24 per share December 27, 2021 313 (37) $0.24 per share January 7, 2021 188 (38) $0.21 per share January 17, 2021 438 (39) $0.16 per share January 30, 2021 625 (40) $0.16 per share February 15, 2021 325,000 (41) $0.1837 per share April 4, 2022 200,000 (42) $0.16 per share April 25, 2022 38,201,847* * Footnote 10 - CONVERTIBLE DEBT IN DEFAULT (1) Issued in June 2015 in exchange for warrants originally issued as part of a May 2013 private placement. (4) Issued as part of a September 2014 Regulation S offering. (5) Issued to a placement agent in conjunction with a 2014 public offering. (6) Issued in June 2015 in exchange for warrants originally issued as part of a 2014 public offering. (7) Issued as part of a March 2015 private placement. (8) Issued to a placement agent in conjunction with a June 2015 private placement. (9) Issued as part of a June 2015 private placement. (10) Issued as part of a June 2015 private placement. (11) Issued as part of a June 2015 private placement. (12) Issued to a placement agent in conjunction with a June 2015 private placement. (13) Issued as part of a June 2015 private placement. (14) Issued to a placement agent in conjunction with a June 2015 private placement. (15) Issued as part of a February 2016 private placement. (16) Issued to a placement agent in conjunction with a February 2016 private placement. (17) (18) Issued pursuant to a strategic license agreement. Issued as part of a February 2017 private placement. (19) Issued as part of a May 2017 private placement. (20) Issued to investors for a loan in November 2017. (21) Issued to investors for a loan in December 2017. (22) Issued to investors for a loan in January 2018. (23) Issued to investors for a loan in March 2018. (24) Issued to investors for a loan in March 2018. (25) Issued to investors for a loan in April 2018. (26) Issued to investors for a loan in May 2018. (27) Issued to investors for a loan in May 2018. (28) Issued to investors for a loan in June 2018 (29) Issued to investors for a loan in August 2018 (30) Issued to investors for a loan in September 2018 (31) Issued to investors for a loan in October 2018 (32) Issued to investors for a loan in November 2018 (33) Issued to investors for a loan in December 2018 (34) Issued to investors for a loan in December 2018 (35) Issued to investors for a loan in December 2018 (36) Issued to investors for a loan in December 2018 (37) Issued to investors for a loan in January 2019 (38) Issued to investors for a loan in January 2019 (39) Issued to investors for a loan in January 2019 (40) Issued to investors for a loan in February 2019 (41) Issued to investors for a loan in April 2019 (42) Issued to investors for a loan in April 2019 All outstanding warrant agreements provide for anti-dilution adjustments in the event of certain mergers, consolidations, reorganizations, recapitalizations, stock dividends, stock splits or other changes in the Company’s corporate structure; except for (8). In addition, warrants subject to footnotes (1) and (9)-(11), (13), and (15) – (42) in the table above are subject to “lower price issuance” anti-dilution provisions that automatically reduce the exercise price of the warrants (and, in the cases of warrants subject to footnote (1), (15) and (16) in the table above, increase the number of shares of common stock issuable upon exercise), to the offering price in a subsequent issuance of the Company’s common stock, unless such subsequent issuance is exempt under the terms of the warrants. For the warrants to footnote (15), the Company further agreed to amend the warrant issued with the original senior secured convertible note, to adjust the number of shares issuable upon exercise of the warrant to equal the number of shares that will initially be issuable upon conversion of the new convertible note (without giving effect to any beneficial ownership limitations set forth in the terms of the new convertible note). The warrants subject to footnote (1) are subject to a mandatory exercise provision. This provision permits the Company, subject to certain limitations, to require exercise of such warrants at any time following (a) the date that is the 30th day after the later of the Company’s receipt of an approvable letter from the U.S. FDA for LuViva and the date on which the common stock achieves an average market price for 20 consecutive trading days of at least $832,000.00 with an average daily trading volume during such 20 consecutive trading days of at least 250 shares, or (b) the date on which the average market price of the common stock for 20 consecutive trading days immediately prior to the date the Company delivers a notice demanding exercise is at least $103,680,000.00 and the average daily trading volume of the common stock exceeds 250 shares for such 20 consecutive trading days. If these warrants are not timely exercised upon demand, they will expire. Upon the occurrence of certain events, the Company may be required to repurchase these warrants, as well as the warrants subject to footnote (1) in the table above. The holders of the warrants subject to footnote (1) in the table above have agreed to surrender the warrants, upon consummation of a qualified public financing, for new warrants exercisable for 200% of the number of shares underlying the surrendered warrants, but without certain anti-dilution protections included with the surrendered warrants. The warrants subject to footnote (4) in the table above are also subject to a mandatory exercise provision. This provision permits the Company, subject to certain limitations; to require the exercise of such warrants should the average trading price of its common stock over any 30-consecutive day trading period exceed $73,728.00. The warrants subject to footnote (6) in the table above are also subject to a mandatory exercise provision. This provision permits the Company, subject to certain limitations, to require exercise of 50% of the then-outstanding warrants if the trading price of its common stock is at least two times the initial warrant exercise price for any 20-day trading period. Further, in the event that the trading price of the Company’s common stock is at least 2.5 times the initial warrant exercise price for any 20-day trading period, the Company will have the right to require the immediate exercise of 50% of the then-outstanding warrants. Any warrants not exercised within the prescribed time periods will be canceled to the extent of the number of shares subject to mandatory exercise. Series B Tranche B Warrants As discussed in Note 3, Fair Value Measurements, between June 13, 2016 and June 14, 2016, the Company entered into various agreements with holders of the Company’s “Series B Tranche B” warrants, pursuant to which each holder separately agreed to exchange the warrants for either (1) shares of common stock equal to 166% of the number of shares of common stock underlying the surrendered warrants, or (2) new warrants exercisable for 200% of the number of shares underlying the surrendered warrants, but without certain anti-dilution protections included with the surrendered warrants. In total, for surrendered warrants then-exercisable for an aggregate of 1,482 shares of common stock (but subject to exponential increase upon operation of certain anti-dilution provisions), the Company issued or is obligated to issue 21 shares of common stock and new warrants that, if exercised as of the date hereof, would be exercisable for an aggregate of 271 shares of common stock. As of June 30, 2019, the Company had issued 18 shares of common stock and rights to common stock shares for 3. In certain circumstances, in lieu of presently issuing all of the shares (for each holder that opted for shares of common stock), the Company and the holder further agreed that the Company will, subject to the terms and conditions set forth in the applicable warrant exchange agreement, from time to time, be obligated to issue the remaining shares to the holder. No additional consideration will be payable in connection with the issuance of the remaining shares. The holders that elected to receive shares for their surrendered warrants have agreed that they will not sell shares on any trading day in an amount, in the aggregate, exceeding 20% of the composite aggregate trading volume of the common stock for that trading day. The holders that elected to receive new warrants will be required to surrender their old warrants upon consummation of the Company’s next financing resulting in net cash proceeds to the Company of at least $1 million. The new warrants will have an initial exercise price equal to the exercise price of the surrendered warrants as of immediately prior to consummation of the financing, subject to customary “downside price protection” for as long as the Company’s common stock is not listed on a national securities exchange and will expire five years from the date of issuance.

5. STOCK OPTIONS

5. STOCK OPTIONS	6 Months Ended
	Jun. 30, 2019
Share-based Payment Arrangement [Abstract]
5. STOCK OPTIONS	The Company’s 1995 Stock Plan (the “Plan”) has expired pursuant to its terms, so zero shares remained available for issuance at June 30, 2019 and December 31, 2018. The Plan allowed for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. Due to the 1:800 reverse stock split of all of the Company’s issued and outstanding common stock was implemented on March 29, 2019. As a result of the reverse stock split, every 800 shares of issued and outstanding common stock were converted into 1 share of common stock. This resulted in the number of stock options outstanding to be zero.

6. LITIGATION AND CLAIMS

6. LITIGATION AND CLAIMS	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
6. LITIGATION AND CLAIMS	From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the dispositions of these matters, individually or in the aggregate, are not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular year. As of June 30, 2019, and December 31, 2018, there was no accrual recorded for any potential losses related to pending litigation.

7. COMMITMENTS AND CONTINGENCIE

7. COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
7. COMMITMENTS AND CONTINGENCIES	Operating Leases In December 2009, the Company moved its offices, which comprise its administrative, research and development, marketing and production facilities to 5835 Peachtree Corners East, Suite B, Peachtree Corners, Georgia 30092. The Company leased approximately 23,000 square feet under a lease that expired in June 2017. In July 2017, the Company leased the offices on a month to month basis. On February 23, 2018, the Company modified its lease to reduce its occupancy to 12,835 square feet. The fixed monthly lease expense will be: $13,859 each month for the period beginning January 1, 2018 and ending March 31, 2018; $8,022 each month for the period beginning April 1, 2018 and ending March 31, 2019; $8,268 each month for the period beginning April 1, 2019 and ending March 31, 2020; and $8,514 each month for the period beginning April 1, 2020 and ending March 31, 2021. The Company recognizes lease expense on a straight-line basis over the estimated lease term and combine lease and non-lease components. Future minimum rental payments at June 30, 2019 under non-cancellable operating leases for office space and equipment are as follows (in thousands): Year Amount 2019 59 2020 120 2021 30 Total 209 Less: Interest 34 Present value of lease liability 175 Related Party Contracts On June 5, 2016, the Company entered into a license agreement with Shenghuo Medical, LLC pursuant to which the Company granted Shenghuo an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Shenghuo was already the Company’s exclusive distributor in China, Macau and Hong Kong, and the license extended to manufacturing in those countries as well. Under the terms of the license agreement, once Shenghuo was capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, Shenghuo would pay the Company a royalty equal to $2.00 or 20% of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within Shenghuo’s exclusive territories. In connection with the license grant, Shenghuo was to underwrite the cost of securing approval of LuViva with Chinese Food and Drug Administration. At its option, Shenghuo also would provide up to $1.0 million in furtherance of the Company’s efforts to secure regulatory approval for LuViva from the U.S. Food and Drug Administration, in exchange for the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million. Pursuant to the license agreement, Shenghuo had the option to have a designee appointed to the Company’s board of directors (former director Richard Blumberg was the designee). As partial consideration for, and as a condition to, the license, and to further align the strategic interests of the parties, the Company agreed to issue a convertible note to Shenghuo, in exchange for an aggregate cash investment of $200,000. The note will provide for a payment to Shenghuo of $300,000, expected to be due the earlier of 90 days from issuance and consummation of any capital raising transaction by the Company with net cash proceeds of at least $1.0 million. The note will accrue interest at 20% per year on any unpaid amounts due after that date. The note will be convertible into shares of the Company’s common stock at a conversion price per share of $11,137, subject to customary anti-dilution adjustment. The note will be unsecured and is expected to provide for customary events of default. The Company will also issue Shenghuo a five-year warrant exercisable immediately for approximately 22 shares of common stock at an exercise price equal to the conversion price of the note, subject to customary anti-dilution adjustment. On January 22, 2017, the Company entered into a license agreement with Shandong Yaohua Medical Instrument Corporation, or SMI, pursuant to which the Company granted SMI an exclusive global license to manufacture the LuViva device and related disposables (subject to a carve-out for manufacture in Turkey) and exclusive distribution rights in the Peoples Republic of China, Macau, Hong Kong and Taiwan. In order to facilitate the SMI agreement, immediately prior to its execution the Company entered into an agreement with Shenghuo Medical, LLC, regarding its previous license to Shenghuo. Under the terms of the new agreement, Shenghuo agreed to relinquish its manufacturing license and its distribution rights in SMI’s territories, and to waive its rights under the original Shenghuo agreement, all for as long as SMI performs under the SMI agreement. On September 6, 2016, the Company entered into a royalty agreement with one of its directors, John Imhoff, and another stockholder, Dolores Maloof, pursuant to which the Company sold to them a royalty of future sales of single-use cervical guides for LuViva. Under the terms of the royalty agreement, and for consideration of $50,000, the Company will pay them an aggregate perpetual royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each disposable that the Company sells (or that is sold by a third party pursuant to a licensing arrangement with the Company).

8. NOTES PAYABLE

8. NOTES PAYABLE	6 Months Ended
	Jun. 30, 2019
Notes Payable [Abstract]
8. NOTES PAYABLE	Long-term Debt – Related Parties During the quarter ended September 30, 2018, the Company entered into an exchange agreement dated July 14, 2018, Dr Faupel, agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $661,000 for a $207,000 promissory note dated September 4, 2018. As a result of the exchange agreement, the Company recorded a gain for extinguishment of debt of $199,000 and a capital contribution of $235,000 during the year ended December 31, 2018. In the July 20, 2018 exchange agreement, Dr, Cartwright, agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $1,621,000 for a $319,000 promissory note dated September 4, 2018. As a result of the exchange agreement, the Company recorded a gain for extinguishment of debt of $840,000 and a capital contribution of $432,000 during the year ended December 31, 2018. In July 2019, the terms of the notes were modified to include simple interest at 6%, with the principal and accrued interest due in total at the date of maturity or September 4, 2021. The table below summarizes the detail of the exchange agreement: For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange $ 661 Amount forgiven during the quarter ended September 30, 2018 (454 ) Promissory note dated September 4, 2018 $ 207 Interest accrued through June 30, 2019 10 Balance outstanding at June 30, 2019 $ 217 For Dr. Cartwright: Salary $ 337 Bonus 675 Interest on compensation 59 Loans to Company 528 Interest on loans 22 Total outstanding prior to exchange $ 1,621 Amount forgiven during the quarter ended September 30, 2018 (1,302 ) Promissory note dated September 4, 2018 $ 319 Interest accrued through June 30, 2019 16 Balance outstanding at June 30, 2019 $ 335 Notes Payable in Default At June 30, 2019 and December 31, 2018, the Company maintained notes payable to both related and non-related parties totaling approximately $715,000 and $700,000, respectively. These notes are short term, straight-line amortizing notes. The notes carry annual interest rates between 0% and 10% and have default rates as high a 20%. The Company is accruing interest at the default rate of 18.0% on two of the loans. The following table summarizes the Notes payable in default, including related parties June 30, 2019 December 31, 2018 Dr. Imhoff $ 199 $ 199 Dr. Cartwright 2 2 Ms. Rosenstock 50 50 Mr. Fowler 26 26 Mr. Mermelstein 226 211 GHS 15 15 GPB 17 17 Aquarius 108 108 Mr. Blumberg 70 70 Mr. James 2 2 Notes payable in default, including related parties $ 715 $ 700 Short Term Notes Payable In July 2018, the Company entered into a premium finance agreement to finance its insurance policies totaling $112,000. The note requires monthly payments of $13,000, including interest at 4.91% and matured in May 2019. As of June 30, 2019, the note for the premium finance agreement was paid in full. The balance due on insurance policies totaled $50,000 at December 31, 2018. On August 22, 2018, the Company issued a promissory note to an investor for $150,000 in aggregate principal amount of a 6% promissory note for an aggregate purchase price of $157,500 (representing a $7,500 original issue discount). Pursuant to the promissory note the entire unpaid principal balance on the promissory note together with all accrued and unpaid interest and loan origination fees, if any, at the choice of the investor, shall be due and payable in full from the funds received by the Company from a financing of at least $2,000,000, or at the option of the investor, to be included in the Company’s financing under the same terms as the new investors with the most favorable terms making a cash investment. If the Company does not complete a financing of at least $2,000,000 within 90 days of the execution of this promissory note, any unpaid amounts shall be due in full to the investor and shall accrue interest at 12% (instead of 6%) per annum from the date thereof (90 days after execution), if not paid in full. In addition, the investor will be granted 1,500,000 warrants under this promissory note. The warrants shall be issued and vest upon the financing of at least $2,000,000 and expire on the third anniversary of said financing. The warrant exercise price shall be set at the same price as for warrants granted to the investors with the most favorable terms as part of any $2,000,000 or more financing of the Company or $0.25, whichever is lower. The warrants shall have standard anti-dilution features to protect the holder from dilution due to down rounds of financing. As of June 30, 2019, and December 31, 2018, the Company had not repaid the note. On September 19, 2018, the Company issued a promissory note to an investor for $50,000 in aggregate principal amount of a 6% promissory note for an aggregate purchase price of $52,500 (representing a $2,500 original issue discount). Pursuant to the promissory note the entire unpaid principal balance on the promissory note together with all accrued and unpaid interest and loan origination fees, if any, at the choice of the investor, shall be due and payable in full from the funds received by the Company from a financing of at least $2,000,000, or at the option of the investor, to be included in the Company’s financing under the same terms as the new investors with the most favorable terms making a cash investment. If the Company does not complete a financing of at least $2,000,000 within 90 days of the execution of this promissory note, any unpaid amounts shall be due in full to the investor and shall accrue interest at 12% (instead of 6%) per annum from the date thereof (90 days after execution), if not paid in full. In addition, the investor will be granted 500,000 warrants under this promissory note. The warrants shall be issued and vest upon the financing of at least $2,000,000 and expire on the third anniversary of said financing. The warrant exercise price shall be set at the same price as for warrants granted to the investors with the most favorable terms as part of any $2,000,000 or more financing of the Company or $0.25, whichever is lower. The warrants shall have standard anti-dilution features to protect the holder from dilution due to down rounds of financing. As of June 30, 2019, and December 31, 2018, the Company had not repaid the note and therefore the accrued interest rate increased to 12%. On February 15, 2019, the Company issued a promissory note to an investor for $50,000 in aggregate principal amount of a 6% promissory note for an aggregate purchase price of $52,500 (representing a $2,500 original issue discount). Pursuant to the promissory note the entire unpaid principal balance on the promissory note together with all accrued and unpaid interest and loan origination fees, if any, at the choice of the investor, shall be due and payable in full from the funds received by the Company from a financing of at least $1,000,000, or at the option of the investor, to be included in the Company’s financing under the same terms as the new investors with the most favorable terms making a cash investment. If the Company does not complete a financing of at least $1,000,000 within 90 days of the execution of this promissory note, any unpaid amounts shall be due in full to the investor and shall accrue interest at 12% (instead of 6%) per annum from the date thereof (90 days after execution), if not paid in full. In addition, the investor will be granted 500,000 warrants under this promissory note. The warrants shall be issued and vest upon the financing of at least $1,000,000 and expire on the third anniversary of said financing. The warrant exercise price shall be set at the same price as for warrants granted to the investors with the most favorable terms as part of any $1,000,000 or more financing of the Company or $0.25, whichever is lower. The warrants shall have standard anti-dilution features to protect the holder from dilution due to down rounds of financing. As of June 30, 2019, the Company had not repaid the note. On February 8, 2019, a note payable in default as reported in the Company’s Form 10-K report - Footnote 9: Notes payable – Note payable in default On February 14, 2019, the Company entered into a Purchase and Sale Agreement with Everest Business Funding for the sale of its accounts receivable. The transaction provided the Company with $48,735 after $1,265 in debt issuance costs (bank costs) for a total purchase amount of $50,000, in which the Company would have to repay $68,500. At a minimum the Company would need to pay $535.16 per day or 20.0% of the future collected accounts receivable or “receipts.” The effective interest rate as calculated for this transaction is approximately 132.5%. As of June 30, 2019, $48,700 had been paid, leaving a balance of $17,883, as well as a discount of $1,822 and unamortized debt issuance costs of $334 remained. At June 30, 2019 and December 31, 2018, the Company also maintained short term notes payable to both related and non-related parties totaling $615,000 and $382,000, respectively. These notes are short term, straight-line amortizing notes. The notes carry annual interest rates between 5% and 12%. The following table summarizes the Short-term notes payable, including related parties June 30, 2019 December 31, 2018 Dr. Imhoff $ 143 $ 135 Dr. Cartwright 14 144 Dr. Faupel 1 123 Ms. Maloof 25 25 Mr. Case 150 150 Mr. Mamula 15 — Mr. Gould 100 50 K2 (Shenghuo) 177 177 Everest 18 — Premium Finance (insurance) — 50 Mr. Blumberg 191 45 Mr. Grimm 30 — Short-term notes payable, including related parties $ 864 $ 899

9. SHORT-TERM CONVERTIBLE DEBT

9. SHORT-TERM CONVERTIBLE DEBT	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
9. SHORT-TERM CONVERTIBLE DEBT	Related Party Convertible Note Payable – Short-Term On June 5, 2016, the Company entered into a license agreement with a distributor pursuant to which the Company granted the distributor an exclusive license to manufacture, sell and distribute the Company’s LuViva Advanced Cervical Cancer device and related disposables in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. The distributor was already the Company’s exclusive distributor in China, Macau and Hong Kong, and the license will extend to manufacturing in those countries as well. As partial consideration for, and as a condition to, the license, and to further align the strategic interests of the parties, the Company agreed to issue a convertible note to the distributor, in exchange for an aggregate cash investment of $200,000. The note will provide for a payment to the distributor of $240,000, due upon consummation of any capital raising transaction by the Company within 90 days and with net cash proceeds of at least $1.0 million. As of June 30, 2019, and December 31, 2018, the Company had a note due of $467,704 and $432,000, respectively. The note accrues interest at 20% per year on any unpaid amounts due after that date. The note will be convertible into shares of the Company’s common stock at a conversion price per share of $11,137.28, subject to customary anti-dilution adjustment. The note will be unsecured and is expected to provide for customary events of default. The Company will also issue the distributor a five-year warrant exercisable immediately for 22 shares of common stock at an exercise price equal to the conversion price of the note, subject to customary anti-dilution adjustment. Convertible Note Payable – Short-Term On March 12, 2018, the Company entered into a securities purchase agreement with Eagle Equities, LLC, providing for the purchase by Eagle of a convertible redeemable note in the principal amount of $66,667. The note was fully funded on March 14, 2018, upon which the Company received $51,000 of net proceeds (net of a 10% original issue discount and other expenses). The note bears an interest rate of 8% and are due and payable on March 12, 2019. The note may be converted by Eagle at any time after twelve months from issuance into shares of our common stock (as determined in the notes) calculated at the time of conversion, except for the second note, which also requires full payment by Eagle of the secured note it issued to us before conversions may be made. The conversion price of the notes will be equal to 60% of the lowest trading price of the common stock for the 20 prior trading days including the day upon which the Company receive a notice of conversion. The notes may be prepaid in accordance with the terms set forth in the notes. The notes also contain certain representations, warranties, covenants and events of default including if the Company are delinquent in our periodic report filings with the SEC and increases in the amount of the principal and interest rates under the notes in the event of such defaults. In the event of default, at Eagle’s option and in its sole discretion, Eagle may consider the notes immediately due and payable. As of June 30, 2019, the notes had been converted and no balance remained outstanding. At December 31, 2018, the outstanding balance was $3,095, including unamortized debt issuance costs of $1,751, and unamortized discount of $1,297 and accrued interest of $177. In addition, as of June 30, 2019 the beneficial conversion feature had been fully amortized. At December 31, 2018, the Company recorded a $44,444 beneficial conversion feature which $35,701 was amortized leaving and unamortized balance of $8,743. As of June 30, 2019, the beneficial conversion feature was fully amortized. On April 5, 2019, the Company entered into a securities purchase agreement with Auctus Fund, LLC for the issuance and sale to Auctus of $65,000 in aggregate principal amount of a 12% convertible promissory note. Funds were received by the Company on April 5, 2019. The note matures on December 29, 2019 and accrues interest at a rate of 12% per year. The Company can prepay the note, in whole or in part, for 115% of outstanding principal and interest until 30 days from issuance, for 125% of outstanding principal and interest at any time from 31 to 60 days from issuance, for 135% of outstanding principal and interest at any time from 61 to 90 days from issuance and for 150% of outstanding principal and interest at any time from 91 days from issuance to 180 days from issuance. The note may not be prepaid after the 180 th On May 15, 2019, the Company entered into a securities purchase agreement with Eagle Equities, LLC, providing for the purchase by Eagle of a convertible redeemable note in the principal amount of $57,750. The note was fully funded on May 21, 2019, upon which the Company received $45,000 of net proceeds (net of a 10% original issue discount and other expenses). The note bears an interest rate of 8% and is due and payable on May 15, 2020. The Company could have prepaid the note, in whole or in part, for 115% of outstanding principal and interest until 30 days from issuance, for 121% of outstanding principal and interest at any time from 31 to 60 days from issuance, for 127% of outstanding principal and interest at any time from 61 to 90 days from issuance, for 133% of outstanding principal and interest at any time from 91 to 120 days from issuance, for 139% of outstanding principal and interest at any time from 121 to 150 days from issuance and for 145% of outstanding principal and interest at any time from 151 days from issuance to 180 days from issuance. The note may not be prepaid after the 180 th On May 15, 2019, the Company entered into a securities purchase agreement with Adar Bays, LLC, providing for the purchase by Adar of a convertible redeemable note in the principal amount of $57,750. The note was fully funded on May 21, 2019, upon which the Company received $45,000 of net proceeds (net of a 10% original issue discount and other expenses). The note bears an interest rate of 8% and are due and payable on May 15, 2020. The Company could have prepaid the note, in whole or in part, for 115% of outstanding principal and interest until 30 days from issuance, for 121% of outstanding principal and interest at any time from 31 to 60 days from issuance, for 127% of outstanding principal and interest at any time from 61 to 90 days from issuance, for 133% of outstanding principal and interest at any time from 91 to 120 days from issuance, for 139% of outstanding principal and interest at any time from 121 to 150 days from issuance and for 145% of outstanding principal and interest at any time from 151 days from issuance to 180 days from issuance. The note may not be prepaid after the 180 th The following table summarizes the Convertible notes payable June 30, 2019 December 31, 2018 Shenghuo $ 468 $ 432 Eagle 58 3 Adar 58 — Auctus 65 — Debt discount and issuance costs to be amortized (33 ) (10 ) Debt discount related to beneficial conversion (96 ) (45 ) Convertible notes payable, including related parties $ 520 $ 380

10. CONVERTIBLE DEBT IN DEFAULT

10. CONVERTIBLE DEBT IN DEFAULT	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
10. CONVERTIBLE DEBT IN DEFAULT	Secured Promissory Note. On September 10, 2014, the Company sold a secured promissory note to an accredited investor with an initial principal amount of $1,275,000, for a purchase price of $700,000 (an original issue discount of $560,000). The Company may prepay the note at any time. The note is secured by the Company’s current and future accounts receivable and inventory, pursuant to a security agreement entered into in connection with the sale. On March 10, 2015, May 4, 2015, June 1, 2015, June 16, 2015, June 29, 2015, January 21, 2016, January 29, 2016, and February 12, 2016 the Company amended the terms of the note to extend the maturity ultimately until August 31, 2016. During the extension, interest accrues on the note at a rate of the lesser of 18% per year or the maximum rate permitted by applicable law. On February 11, 2016, the Company consented to an assignment of the note to two accredited investors. In connection with the assignment, the holders waived an ongoing event of default under the notes related to the Company’s minimum market capitalization and agreed to eliminate the requirement going forward. Pursuant to the terms of the amended note, the holder may convert the outstanding balance into shares of common stock at a conversion price per share equal to the lower of (1) $20,000.00 or (2) 75% of the lowest daily volume weighted average price of the common stock during the five days prior to conversion. If the conversion price at the time of any conversion is lower than $12,000.00, the Company has the option of delivering the conversion amount in cash in lieu of shares of common stock. On March 7, 2016, the Company further amended the note to eliminate the volume limitations on sales of common stock issued or issuable upon conversion. On July 13, 2016, the Company consented to the assignment by one of the accredited investors of its portion of the note of to a third accredited investor. The balance due on the note was $166,039 and $151,974 at June 30, 2019 and December 31, 2018, respectively. The balance was reduced by $306,863 as part of a debt restructuring on December 7, 2016. Total debt issuance costs as originally capitalized were approximately $130,000. This amount was amortized over nine months and was fully amortized as of December 31, 2015. The original issue discount of $560,000 was fully amortized as of December 31, 2015. On November 2, 2016, the Company entered into a lockup and exchange agreement with GHS Investments, LLC, holder of approximately $221,000 in outstanding principal amount of the Company’s secured promissory note and all the outstanding shares of the its Series C preferred stock. Pursuant to the agreement, upon the effectiveness of the 1:800 reverse stock split and continuing for 45 days after, GHS and its affiliates were prohibited from converting any portion of the secured promissory note or any of the shares of Series C preferred stock or selling any of the Company’s securities that they beneficially owned. The Company agreed that, upon consummation of its next financing, the Company would use $260,000 of net cash proceeds first, to repay GHS’s portion of the secured promissory note and second, with any remaining amount from the $260,000, to repurchase a portion of GHS’s shares of Series C preferred stock. In addition, GHS has agreed to exchange the stated value per share (plus any accrued but unpaid dividends) of its remaining shares of Series C preferred stock for new securities of the same type that the Company separately issue in the next qualifying financing it undertakes, on a dollar-for-dollar basis in a private placement exchange. Senior Secured Promissory Note On February 11, 2016, the Company entered into a securities purchase agreement with GPB Debt Holdings II LLC for the issuance and sale on February 12, 2016 of $1.4375 million in aggregate principal amount of a senior secured convertible note for an aggregate purchase price of $1.15 million (a 20% original issue discount of $287,500) and a discount for debt issuance costs paid at closing of $121,000 for a total of $408,500. In addition, GPB received a warrant exercisable to purchase an aggregate of approximately 2,246 shares of the Company’s common stock. The Company allocated proceeds totaling $359,555 to the fair value of the warrants at issuance. This was recorded as an additional discount on the debt. The convertible note matures on the second anniversary of issuance and, in addition to the 20% original issue discount, accrues interest at a rate of 17% per year. The Company is required to pay monthly interest coupons and beginning nine months after issuance, the Company is required to pay amortized quarterly principal payments. If the Company does not receive, on or before the first anniversary after issuance, an aggregate of at least $3.0 million from future equity or debt financings or non-dilutive grants, then the holder will have the option of accelerating the maturity date to the first anniversary of issuance. The Company may prepay the convertible note, in whole or in part, without penalty, upon 20 days’ prior written notice. Subject to resale restrictions under Federal securities laws and the availability of sufficient authorized but unissued shares of the Company’s common stock, the convertible note is convertible at any time, in whole or in part, at the holder’s option, into shares of the Company’s common stock, at a conversion price equal to the lesser of $640.00 per share or 70% of the average closing price per share for the five trading days prior to issuance, subject to certain customary adjustments and anti-dilution provisions contained in the convertible note. On May 28, 2016, in exchange for an additional $87,500 in cash from GPB to the Company, the principal balance was increased by the same amount. The Company is currently in default as they are past due on the required monthly interest payments. In the event of default, the Company shall accrue interest at a rate the lesser of 22% or the maximum permitted by law. The Company has accrued $117,000 for past due interest payments at December 31, 2016. Upon the occurrence of an event of default, the holder may require the Company to redeem the convertible note at 120% of the outstanding principal balance (but as of June 30, 2019, had not done so). As of June 30, 2019, the balance due on the convertible debt was $2,177,030 as the Company has fully amortized debt issuance costs of $47,675 and the debt discount of $768,055 and recorded a 20% penalty totaling $366,373. In addition, the Company has accrued $943,485 of interest expense for the period ended June 30, 2019. As of December 31, 2018, the balance due on the convertible debt was $2,198,236. In addition, the Company had accrued $699,743 of interest expense for the year ended December 31, 2018. The convertible note is secured by a lien on all the Company’s assets, including its intellectual property, pursuant to a security agreement entered into by the Company and GPB. The warrant is exercisable at any time, pending availability of sufficient authorized but unissued shares of the Company’s common stock, at an exercise price per share equal to the conversion price of the convertible note, subject to certain customary adjustments and anti-dilution provisions contained in the warrant. The warrant has a five-year term. As of June 30, 2019, the exercise price had been adjusted to $0.04 and the number of common stock shares exchangeable for was 35,937,500. As of June 30, 2019, and December 31, 2018, the effective interest rate considering debt costs was 29%. The Company used a placement agent in connection with the transaction. For its services, the placement agent received a cash placement fee equal to 4% of the aggregate gross proceeds from the transaction and a warrant to purchase shares of common stock equal to an aggregate of 6% of the total number of shares underlying the securities sold in the transaction, at an exercise price equal to, and terms otherwise identical to, the warrant issued to the investor. Finally, the Company agreed to reimburse the placement agent for its reasonable out-of-pocket expenses. In connection with the transaction, on February 12, 2016, the Company and GPB entered into a four-year consulting agreement, pursuant to which the investor will provide management consulting services to the Company in exchange for a royalty payment, payable quarterly, equal to 3.85% of the Company’s revenues from the sale of products. As of June 30, 2019, and 2018, GPB had earned approximately $32,000 and $31,000 in royalties, respectively. Debt Restructuring On December 7, 2016, the Company entered into an exchange agreement with GPB with regard to the $1,525,000 in outstanding principal amount of senior secured convertible note originally issued to GPB on February 11, 2016, and the $306,863 in outstanding principal amount of the Company’s secured promissory note that GPB holds (see “—Secured Promissory Note”). Pursuant to the exchange agreement, upon completion of the next financing resulting in at least $1.0 million in cash proceeds, GPB will exchange both securities for a new convertible note in principal amount of $1,831,863. The new convertible note will mature on the second anniversary of issuance and will accrue interest at a rate of 17% per year. The Company will pay monthly interest coupons and, beginning one year after issuance, will pay amortized quarterly principal payments. Subject to resale restrictions under Federal securities laws and the availability of sufficient authorized but unissued shares of the Company’s common stock, the new convertible note will be convertible at any time, in whole or in part, at the holder’s option, into shares of common stock, at a conversion price equal to the price offered in the qualifying financing that triggers the exchange, subject to certain customary adjustments and anti-dilution provisions contained in the new convertible note. The new convertible note will include customary event of default provisions and a default interest rate of the lesser of 22% or the maximum amount permitted by law. Upon the occurrence of an event of default, GPB will be entitled to require the Company to redeem the new convertible note at 120% of the outstanding principal balance. The new convertible note will be secured by a lien on all the Company’s assets, including its intellectual property, pursuant to the security agreement entered into by the Company and GPB in connection with the issuance of the original senior secured convertible note. Additionally, the Company further agreed to amend the warrant issued with the original senior secured convertible note, to adjust the number of shares issuable upon exercise of the warrant to equal the number of shares that will initially be issuable upon conversion of the new convertible note (without giving effect to any beneficial ownership limitations set forth in the terms of the new convertible note). As an inducement to GPB to enter into these transactions, the Company agreed to increase the royalty payable to GPB pursuant to its consulting agreement with us on December 7, 2016 from 3.5% to 3.85% of revenues from the sales of the Company’s products. On August 8, 2017, the Company entered into a forbearance agreement with GPB, with regard to the senior secured convertible note. Under the forbearance agreement, GPB has agreed to forbear from exercising certain of its rights and remedies (but not waive such rights and remedies), arising as a result of the Company’s failure to pay the monthly interest due and owing on the note. In consideration for the forbearance, the Company agreed to waive, release, and discharge GPB from all claims against GPB based on facts existing on or before the date of the forbearance agreement in connection with the note, or the dealings between the Company and GPB, or the Company’s equity holders and GPB, in connection with the note. Pursuant to the forbearance agreement, the Company has reaffirmed its obligations under the note and related documents and executed a confession of judgment regarding the amount due under the note, which GPB may file upon any future event of default by the Company. During the forbearance period, the Company must continue to comply will all the terms, covenants, and provisions of the note and related documents. The “Forbearance Period” shall mean the period beginning on the date hereof and ending on the earliest to occur of: (i) the date on which Lender delivers to Company a written notice terminating the Forbearance Period, which notice may be delivered at any time upon or after the occurrence of any Forbearance Default (as hereinafter defined), and (ii) the date Company repudiates or asserts any defense to any Obligation or other liability under or in respect of this Agreement or the Transaction Documents or applicable law, or makes or pursues any claim or cause of action against Lender; (the occurrence of any of the foregoing clauses (i) and (ii), a “Termination Event”). As used herein, the term “Forbearance Default” shall mean: (A) the occurrence of any Default or Event of Default other than the Specified Default; (B) the failure of Company to timely comply with any material term, condition, or covenant set forth in this Agreement; (C) the failure of any representation or warranty made by Company under or in connection with this Agreement to be true and complete in all material respects as of the date when made; or (D) Lender’s reasonable belief that Company: (1) has ceased or is not actively pursuing mutually acceptable restructuring or foreclosure alternatives with Lender; or (2) is not negotiating such alternatives in good faith. Any Forbearance Default will not be effective until one (1) Business Day after receipt by Company of written notice from Lender of such Forbearance Default. Any effective Forbearance Default shall constitute an immediate Event of Default under the Transaction Documents. Other Convertible Debt in Default On May 18, 2017, the Company entered into a securities purchase agreement with GHS Investments, LLC, an existing investor, providing for the purchase by GHS of a convertible promissory note in the aggregate principal amount of $66,000, for $60,000 in net proceeds (representing a 10% original issue discount). The transaction closed on May 19, 2017. The note matures upon the earlier of our receipt of $100,000 from revenues, loans, investments, or any other means (other than the Eagle and Adar bridge financings) and December 31, 2017. In addition to the 10% original issue discount, the note accrues interest at a rate of 8% per year. The Company may prepay the note, in whole or in part, for 110% of outstanding principal and interest until 30 days from issuance, for 120% of outstanding principal and interest at any time from 31 to 60 days from issuance and for 140% of outstanding principal and interest at any time from 61 days to 180 days from issuance. The note may not be prepaid after 180 days. After six months from the date of issuance, the note will become convertible, at any time thereafter, in whole or in part, at the holder’s option, into shares of our common stock, at a conversion price equal to 60% of the lowest trading price during the 25 trading days prior to conversion. The note includes customary event of default provisions and a default interest rate of the lesser of 20% per year or the maximum amount permitted by law. Upon the occurrence of an event of default, the holder of the note may require us to redeem the note (or convert it into shares of common stock) at 150% of the outstanding principal balance. As of June 30, 2019, the Company’s total outstanding amount was $83,094, (which includes $37,926 for a default penalty) and accrued interest of $7,422. GHS converted $12,700 of principal and accrued interest payable for the six months ended June 30, 2019. This was compared with a total outstanding amount of $94,411, (which includes $37,926 for a default penalty) and accrued interest of $517 as of December 31, 2018. GHS converted $29,642 of principal and accrued interest payable for the period ended December 31, 2018. On March 20, 2018, the Company entered into a securities purchase agreement with Auctus Fund, LLC for the issuance and sale to Auctus of $150,000 in aggregate principal amount of a 12% convertible promissory note. On March 20, 2018, the Company issued the note to Auctus. Pursuant to the purchase agreement, the Company also issued to Auctus a warrant exercisable to purchase an aggregate of 4,262 shares of the Company’s common stock. The warrant is exercisable at any time, at an exercise price per share equal to $0.04, subject to certain customary adjustments and price-protection provisions contained in the warrant. The warrant has a five-year term. The note matures nine months from the date of issuance and accrues interest at a rate of 12% per year. The Company could have prepaid the note, in whole or in part, for 115% of outstanding principal and interest until 30 days from issuance, for 125% of outstanding principal and interest at any time from 31 to 60 days from issuance, and for 130% of outstanding principal and interest at any time from 61 days from issuance to 180 days from issuance. After nine months from the date of issuance, Auctus may convert the note, at any time, in whole or in part, into shares of the Company’s common stock, at a conversion price equal to the lower of the price offered in the Company’s next public offering or a 40% discount to the average of the two lowest trading prices of the common stock during the 20 trading days prior to the conversion, subject to certain customary adjustments and price-protection provisions contained in the note. The note includes customary events of default provisions and a default interest rate of 24% per year. Upon the occurrence of an event of default, Auctus may require the Company to redeem the note (or convert it into shares of common stock) at 150% of the outstanding principal balance plus accrued and unpaid interest. As of June 30, 2019, the Company has a net debt of $192,267 (which includes $70,931 for a default premium) and accrued interest of $22,044. Auctus converted $14,237 of principal and accrued interest payable for the six months ended June 30, 2019. As of December 31, 2018, the Company had a net debt of $133,870 and accrued interest of $635. Auctus converted $30,152 of principal and accrued interest payable for the period ended December 31, 2018. In addition, at December 31, 2018, the Company recorded a $97,685 beneficial conversion feature which was fully amortized at year end. Upon the occurrence of an event of default, Auctus may require the Company to redeem the note (or convert it into shares of common stock) at 150% of the outstanding principal balance plus accrued and unpaid interest, this has not occurred as of the date of this Form 10-Q quarterly report. On May 17, 2018, the Company entered into a securities purchase agreement with GHS Investments, LLC, an existing investor, providing for the purchase by GHS of a convertible promissory note in the aggregate principal amount of $9,250 (with $750 representing a 10% original issue discount and $1,000 for transaction costs). The note matured on June 17, 2019. In addition to the 10% original issue discount, the note accrues interest at a rate of 10% per year. The Company may prepay the note, in whole or in part, for 110% of outstanding principal and interest until 30 days from issuance, for 120% of outstanding principal and interest at any time from 31 to 60 days from issuance and for 140% of outstanding principal and interest at any time from 61 days to 180 days from issuance. The note may not be prepaid after 180 days. After nine months from the date of issuance, the note will become convertible, at any time thereafter, in whole or in part, at the holder’s option, into shares of our common stock, at a conversion price equal to 30% of the lowest trading price during the 25 trading days prior to conversion (if note cannot be converted due to issues with DTC then rate increases to 40%). The note includes customary event of default provisions and a default interest rate of the lesser of 20% per year or the maximum amount permitted by law. Upon the occurrence of an event of default, the holder of the note may require us to redeem the note (or convert it into shares of common stock) at 150% of the outstanding principal balance. As of June 30, 2019, the Company has a net debt of $14,187 (which includes $4,937 for a default penalty), and accrued interest of $2,542. As of December 31, 2018, the Company had a net debt of $14,187 (which includes $4,937 for a default penalty), including unamortized debt issuance costs of $424, unamortized discount of $318 and accrued interest of $1,135. In addition, as of June 30, 2019 the beneficial conversion feature of $3,964 had been fully amortized. At December 31, 2018, $2,280 was amortized leaving and unamortized balance of $1,685. On June 22, 2018, the Company entered into a securities purchase agreement with GHS Investments, LLC, an existing investor, providing for the purchase by GHS of a convertible promissory note in the aggregate principal amount of $68,000 (with $6,000 representing a 10% original issue discount and $2,000 for transaction costs). The note matured on June 22, 2019. In addition to the 10% original issue discount, the note accrues interest at a rate of 10% per year. The Company may prepay the note, in whole or in part, for 110% of outstanding principal and interest until 30 days from issuance, for 120% of outstanding principal and interest at any time from 31 to 60 days from issuance and for 140% of outstanding principal and interest at any time from 61 days to 180 days from issuance. The note may not be prepaid after 180 days. After nine months from the date of issuance, the note will become convertible, at any time thereafter, in whole or in part, at the holder’s option, into shares of our common stock, at a conversion price equal to 30% of the lowest trading price during the 25 trading days prior to conversion (if note cannot be converted due to issues with DTC then rate increases to 40%). The note includes customary event of default provisions and a default interest rate of the lesser of 20% per year or the maximum amount permitted by law. Upon the occurrence of an event of default, the holder of the note may require us to redeem the note (or convert it into shares of common stock) at 150% of the outstanding principal balance. As of June 30, 2019, the Company has a net debt of $103,285 (which includes $35,285 for a default penalty), and accrued interest of $18,506. As of December 31, 2018, the Company had a net debt of $103,285 (which includes $35,285 for a default penalty), including unamortized debt issuance costs of $3,318, unamortized discount of $2,844 and accrued interest of $8,263. In addition, as of June 30, 2019 the beneficial conversion feature of $29,143 had been fully amortized. At December 31, 2018, $15,288 was amortized leaving an unamortized balance of $13,855. On July 3, 2018, the Company entered into a securities purchase agreement with Auctus Fund, LLC for the issuance and sale to Auctus of $89,250 in aggregate principal amount of a 12% convertible promissory note. On July 3, 2018, the Company issued the note to Auctus. The note matured on April 3, 2019 and accrues interest at a rate of 12% per year. The Company could have prepaid the note, in whole or in part, for 115% of outstanding principal and interest until 30 days from issuance, for 125% of outstanding principal and interest at any time from 31 to 60 days from issuance, and for 130% of outstanding principal and interest at any time from 61 days from issuance to 180 days from issuance. After nine months from the date of issuance, Auctus may convert the note, at any time, in whole or in part, into shares of the Company’s common stock, at a conversion price equal to the lower of the price offered in the Company’s next public offering or a 40% discount to the average of the two lowest trading prices of the common stock during the 20 trading days prior to the conversion, subject to certain customary adjustments and price-protection provisions contained in the note. The note includes customary events of default provisions and a default interest rate of 24% per year which went into effect on April 3, 2019. Upon the occurrence of an event of default, Auctus may require the Company to redeem the note (or convert it into shares of common stock) at 150% of the outstanding principal balance plus accrued and unpaid interest. As of June 30, 2019, the Company has a net debt of $146,102 and accrued interest of $4,266. As of December 31, 2018, the Company had a net debt of $81,528, including unamortized original issue discount of $1,443, unamortized debt issuance costs of $6,279 and accrued interest of $5,385. In addition, as of June 30, 2019 the beneficial conversion feature of $59,500 had an unamortized balance of $434. At December 31, 2018, $39,233 was amortized leaving and unamortized balance of $20,267. Upon the occurrence of an event of default, Auctus may require the Company to redeem the note (or convert it into shares of common stock) at 150% of the outstanding principal balance plus accrued and unpaid interest, this has not occurred as of this Form 10-Q quarterly report. The following table summarizes the Convertible notes in default June 30, 2019 December 31, 2018 GPB $ 2,177 $ 2,198 GHS 367 364 Auctus 338 223 Debt Discount to be amortized — (7 ) Convertible notes in default $ 2,882 $ 2,778

11. INCOME (LOSS) PER COMMON SH

11. INCOME (LOSS) PER COMMON SHARE	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
11. INCOME (LOSS) PER COMMON SHARE	Basic net income (loss) per share attributable to common stockholders amounts are computed by dividing the net income (loss) plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of shares outstanding during the period. Diluted net income (loss) per share attributable to common stockholders amounts are computed by dividing the net income (loss) plus preferred stock dividends, deemed dividends on preferred stock, after-tax interest on convertible debt and convertible dividends by the weighted average number of shares outstanding during the period, plus Series C convertible preferred stock, convertible debt, convertible preferred dividends and warrants convertible into common stock shares. The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders. In thousands Six months ended June 30, 2019 2018 Net (loss) income $ (2,878 ) $ 4,404 Basic weighted average number of shares outstanding 3,319 179 Net (loss) income per share (basic) $ (0.87 ) $ 24.60 Diluted weighted average number of shares outstanding 3,319 2,999 Net (loss) income per share (diluted) $ (0.87 ) $ 1.47 Dilutive equity instruments (number of equivalent units): Stock options — — Preferred stock — 368 Convertible debt 38,786 1,704 Warrants 30,235 748 Total Dilutive instruments 69,021 2,820

12. SUBSEQUENT EVENTS

12. SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
12. SUBSEQUENT EVENTS	On July 1, 2019, the Company entered into a loan agreement with Accilent Capital Management Inc / Rev Royalty Income and Growth Trust (“Accilent”), providing for the purchase by Rev of an unsecured promissory note in the principal amount of $49,389 (CAD$ 65,500) . The note was fully funded on July 9, 2019 (net of a 8% original issue discount and other expenses). The note bears an interest rate of 16% and are due and payable on September 11, 2019. The Company could have prepaid the note, with three months of interest as a penalty. Following maturity, demand, default, or judgment and until actual payment in full, interest rate shall be paid at the rate of 19% per annum. The Company will issue warrants to purchase one common share of the Company for each warrant held in the aggregate amount of 215,000 warrants at an exercise price of $0.25 per warrant, or alternatively, the same price as for warrants granted to investors as part of a financing of the Company subject to adjustment and exercisable within 3 years from issuance (the “Initial Warrants”). In the event that the common shares of the Issuer are not listed on the TSX Venture Exchange pursuant to the “Transaction” on or prior to September 1, 2019, an additional 100,000 warrants will be issued at an exercise price equal to the lesser of $0.25 or the price of the next issuance of common shares of the Issuer (the “Revised Exercise Price”). Further, the exercise price of the Initial Warrants will adjust to the Revised Exercise Price has stated herein. On July 24, 2019, Mr. Cartwright and Mr. Faupel agreed to an addendum to the exchange agreement and to modify the terms of the original exchange agreement. Under this modification Mr. Cartwright and Mr. Faupel agreed to extend the note to be due in full on the third anniversary of that agreement. On July 24, 2019, Shandong Yaohua Medical Instrument Corporation (“SMI”), agreed to modify its existing agreement. Under the terms of this modification, the Company agreed to grant (1) exclusive manufacturing rights, excepting the disposable cervical guides for the Republic of Turkey, and the final assembly rights for Hungary, and (2) exclusive distribution and sales for LuViva in jurisdictions, subject to the following terms and conditions. First, SMI shall complete the payment for parts, per the purchase order, for five additional LuViva devices. Second, in consideration for the $885,144 that the Company received, SMI will receive 12,147 common stock shares. Third, SMI shall honor all existing purchase orders it has executed to date with the Company, in order to maintain jurisdiction sales and distribution rights. If SMI needs cervical guides then it will do so at a cost including labor, plus ten percent markup. The Company will provide 200 cervical guides at no cost for the clinical trials. Fourth, the Company and SMI will make best efforts to sell devices after CFDA approval. With an initial estimate of year one sales of 200 LuViva devices; year two sales of 500 LuViva devices; year three sales of 1,000 LuViva devices; and year four sales of 1,250 LuViva devices. Fifth, SMI shall pay for entire costs of securing approval of LuViva with the Chinese FDA. Sixth, SMI shall arrange, at its sole cost, for a manufacturer in China to build tooling to support manufacture. In addition, SMI retains the right to manufacture for China, Hong Kong, Macau and Taiwan, where SMI has distribution and sales rights. For each single-use cervical guide sold by SMI in the jurisdictions, SMI shall transfer funds to escrow agent at a rate of $1.90 per chip. If within 18 months of the license’s effective date, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Commercialization is defined as: Filing an application with the Chinese FDA for the approval of LuViva; Any assembly or manufacture of the devices or disposables that begins in China; and purchase of at least 10 devices and disposables for clinical evaluations and regulatory use and or sales in the jurisdictions. The Company had recorded an accrued liability for SMI of $692,335, which will be reclassified to additional paid in capital and 12,147 common stock shares. In addition, after June 30, 2019, the Company entered into promissory notes with investors and related parties for a total of $55,000. On December 17, 2019, the Company entered into a securities purchase agreement and convertible note with Auctus. The convertible note issued to Auctus will be for a total of $2.4 million. The first tranche of $700,000 has been received and will have a maturity date of December 17, 2021 and an interest rate of ten percent (10%). The note may not be prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of the lessor of 24% and the maximum permitted by law (the “default interest”). The variable conversion prices shall equal the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price shall mean 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event shall the variable conversion price be less than $0.015. If an event of default under this note occurs and/or the note is not extinguished in its entirety prior to December 17, 2020 the $0.15 price shall no longer apply. In addition, Auctus will receive 7,500,000 five-year common stock purchase warrants, at an exercise price of $0.20, on the first tranche of $700,000. From the $700,000, the Company shall receive $570,000, $65,000 will go to attorney’s fees and Auctus Fund Management, and $65,000 will be paid for the partial payment of an $89,250 promissory note that was issued on July 3, 2018 to Auctus. At a future date, the second tranche of $400,000 will be received when the Company files its S-1 registration statement. The last tranche of $1.3 million will be received within 60 days of the S-1 registration statement becoming effective. The conversion price of the notes will be at market value with a minimum conversion amount of $0.15. The last two tranches will have warrants attached. During December 2019 and January 2020, the Company received equity investments in the amount of $738,000. These investors received a total of 1,476,000 common stock shares and 1,476,000 warrants to purchase common stock shares at a strike price of $0.25 and 1,476,000 warrants to purchase common stock shares at a strike price of $0.75. Of the amount invested $388,000 was from related parties. During the fourth quarter of 2019 and January 2020, the Company entered into the exchange agreements listed below. On December 5, 2019, the Company entered into an exchange agreement with Aquarius. Based on this agreement the Company will exchange $145,544 of debt outstanding for: 291,088 common stock shares; 145,544 warrants to purchase common stock shares at a strike price of $0.25; and 145,544 warrants to purchase common stock shares at a strike price of $0.75. On December 30, 2019, the Company entered into an exchange agreement with K2 Medical. Based on this agreement the Company will exchange $803,654 of debt outstanding for: 1,905,266 common stock shares; 496,600 warrants to purchase common stock shares at a strike price of $0.20; 704,3334 warrants to purchase common stock shares at a strike price of $0.25; and 704,333 warrants to purchase common stock shares at a strike price of $0.75. On December 30, 2019, the Company entered into an exchange agreement with Mr. Blumberg. Based on this agreement the Company will exchange $305,320 of debt outstanding for: 1,167,630 common stock shares; 928,318 warrants to purchase common stock shares at a strike price of $0.20; 119,656 warrants to purchase common stock shares at a strike price of $0.25; and 119,656 warrants to purchase common stock shares at a strike price of $0.75. On December 30, 2019, the Company entered into an exchange agreement with Mr. Case. Based on this agreement the Company will exchange $179,291 of debt outstanding for: 896,455 common stock shares; and 896,455 warrants to purchase common stock shares at a strike price of $0.20. On December 30, 2019, the Company entered into an exchange agreement with Mr. Grimm. Based on this agreement the Company will exchange $51,110 of debt outstanding for: 255,548 common stock shares; and 255,548 warrants to purchase common stock shares at a strike price of $0.20. On December 30, 2019, the Company entered into an exchange agreement with Mr. Gould. Based on this agreement the Company will exchange $111,557 of debt outstanding for: 556,136 common stock shares; and 556,136 warrants to purchase common stock shares at a strike price of $0.20. On December 30, 2019, the Company entered into an exchange agreement with Mr. Mamula. Based on this agreement the Company will exchange $15,577 of debt outstanding for: 77,885 common stock shares; and 77,885 warrants to purchase common stock shares at a strike price of $0.20. On December 30, 2019, the Company entered into an exchange agreement with Mr. Imhoff. Based on this agreement the Company will exchange $400,417 of debt outstanding for: 1,699,255 common stock shares; 1,497,367 warrants to purchase common stock shares at a strike price of $0.20; 100,944 warrants to purchase common stock shares at a strike price of $0.25; and 100,944 warrants to purchase common stock shares at a strike price of $0.75. On December 30, 2019, the Company entered into an exchange agreement with Ms. Rosenstock. Based on this agreement the Company will exchange $78,986 of debt outstanding for: 100,000 common stock shares; and 100,000 warrants to purchase common stock shares at a strike price of $0.25; and 100,000 warrants to purchase common stock shares at a strike price of $0.75. On January 6, 2020, the Company entered into an exchange agreement with Jones Day. The Company will exchange $1,744,768 of debt outstanding for: $175,000, an unsecured promissory note in the amount of $550,000; due 13 months form the date of issuance, that may be called by the Company at any time prior to maturity upon a payment of $150,000; and an unsecured promissory note in the principal amount of $444,768, bearing an annualized interest rate of 6.0% and due in four equal annual installments beginning on the second anniversary of the date of issuance. On January 16, 2020, the Company entered into an exchange agreement with GPB. Based on this agreement the Company will exchange $3,360,811 of debt outstanding for: cash of $1,500,000; 1,860,811 common stock shares; 7,185,000 warrants to purchase common stock shares at a strike price of $0.20; 1,860,811 warrants to purchase common stock shares at a strike price of $0.25; 3,721,622 warrants to purchase common stock shares at a strike price of $0.75; and 2,791 series D preferred stock shares. If the Company is able to raise capital in excess of $4,000,000, the exchange amounts shall be adjusted. If the financing is between $4,000,000 and $4,900,000, for every $100,000 raised in excess of $4,000,000 the Company will pay an additional $50,000 to pay down debt. If between $5,000,000 and $6,000,000 is raised thru financings, the Company will pay an additional $1,000,000 to pay down debt. If the financing is in excess of $6,000,000 then the Company will pay the entire debt balance outstanding. In the event of alternative financings, the Company may elect to pay GPB a total of $1,500,000 in cash to GPB at which time GPB shall waive any security interest in the assets of the Company, and GPB shall exchange any remaining debt from the notes into the Series D unit offering. GPB shall have the right to convert the outstanding notes into equity, but not the obligation. A 9.99% blocker shall be in effect such that GPB agrees to restrict its holdings of the Company’s common stock shares to less than 9.99% of the total number of the Company’s outstanding common stock shares at any one point in time. All royalty payments owed to GPB pursuant thereto shall remain obligations of the Company to GPB and shall remain in full force and effect. The Company shall have 8 months from the execution date of this exchange agreement, subject to early termination as forth below (in “forbearance agreement”). The Company shall be entitled to extend the forbearance agreement for four additional months for a $50,000 per month payment. If after the financing is completed and in the event of future financings or significant collaborations with a partner generating sales greater than $1,000,000, the Company agrees to buy back $500,000 of the Series D preferred stock shares. The interest rate will revert to their original non default rates. Also, all existing warrants issued prior to exchange agreement will be canceled. In addition, the Company is negotiating additional exchange agreements that would potentially eliminate or convert debt into equity; as well as convert certain forms of equity for other equity. On January 22, 2020, the Company entered into a promotional agreement with a consultant. The consultant will provide the Company investor and public relations services. As compensation for these services, the Company will issue a total of 5,000,000 common stock warrants at a $0.25 strike price and expiring in three years, if the following conditions occur: 1,250,000 common stock warrants, 6 months after the close of the Series D Preferred Stock units, if the minimum common stock share price is a minimum of $0.50 based on a 30-day VWAP, with a two year term; 1,250,000 common stock warrants, 12 months after the close of the Series D Preferred Stock units, if the minimum common stock share price is a minimum of $0.75 based on a 30-day VWAP, with a one and half year term; 1,250,000 common stock warrants, 18 months after the close of the Series D Preferred Stock units, if the minimum common stock share price is a minimum of $1.00 based on a 30-day VWAP, with a one year term; and 1,250,000 common stock warrants, 24 months after the close of the Series D Preferred Stock units, if the minimum common stock share price is a minimum of $1.25 based on a 30-day VWAP, with a one year term. The consultant agrees to a 10.0% blocker at any single point in time it cannot own 10.0% of the total common stock shares outstanding.

2. SIGNIFICANT ACCOUNTING POL_2

2. SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants.
Principles of Consolidation	The accompanying consolidated financial statements include the accounts of Guided Therapeutics, Inc. and its wholly owned subsidiary. All intercompany transactions are eliminated.
Accounting Standards Updates	Implemented In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” that requires lessees to recognize on the balance sheet the assets and liabilities associated with the rights and obligations created by those leases. Under the new guidance, a lessee is required to recognize assets and liabilities for leases with lease terms of more than 12 months. Consistent with current U.S. GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily depends on its classification as finance or operating lease. The update is effective for reporting periods beginning after December 15, 2018. The a Except as noted above, the guidance issued by the FASB during the current year is not expected to have a material effect on the Company’s consolidated financial statements. A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any, that the implementation of such proposed standards would have on the Company’s consolidated financial statements.
Cash Equivalents	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
Accounts Receivable	The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. The Company does not accrue interest receivable on past due accounts receivable.
Concentrations of Credit Risk	The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
Inventory Valuation	All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. At June 30, 2019 and December 31, 2018, our inventories were as follows (in thousands): June 30, December 31, 2019 2018 Raw materials $ 781 $ 783 Work in process 81 81 Finished goods 17 17 Inventory reserve (831 ) (767 ) Total $ 48 $ 114 The Company maintains reserves for excess and obsolete inventories to reflect inventory at . The Company’s estimate for excess and obsolete inventory is based upon the assumptions about future demand and market conditions. The establishment of a reserve for excess and obsolete inventory establishes a new cost basis in the inventory. Such reserves are not reduced until the product is sold. If the Company was able to sell such inventory any related reserves would be reversed in the period of sale.
Property and Equipment	Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the consolidated statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at June 30, 2019 and December 31, 2018 (in thousands): June 30, December 31, 2019 2018 Equipment $ 1,349 $ 1,378 Software 740 740 Furniture and fixtures 124 124 Leasehold Improvement 180 199 2,393 2,441 Less accumulated depreciation and amortization (2,393 ) (2,420 ) Total $ — $ 21
Debt Issuance Costs	Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the consolidated balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount.
Other Assets	Other assets primarily consist of a deposit for the corporate office.
Patent Costs (Principally Legal Fees)	Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs aggregated approximately $10,000 and $7,000 for the six months ended June 30, 2019 and 2018, respectively.
Leases	With the implementation of ASU 2016-02, “Leases (Topic 842)”, the Company recorded a lease asset-right and a lease liability. The implementation required the analysis of certain criteria in determining its treatment. The Company determined that its corporate office lease met those criteria. The Company implemented the guidance using the alternative transition method. Under this alternative, the effective date would be the date of initial application. The Company analyzed the lease at its effective date and calculated an initial lease payment amount of $267,380 with a present value of $213,000 using a 20% discount. As of June 30, 2019, the balance of the lease asset – right and lease liability was approximately $175,000. Rent was unpaid as of June 30, 2019, and therefore the Company is including rent in accounts payable. The cumulative effect of initially applying the new guidance had an immaterial impact on the opening balance of retained earnings, The Company does not expect the guidance to have a material impact on its consolidated net earnings in future periods. The Company elected the Practical expedients permitted under the transition guidance within the new standards, which allowed the Company to carry forward the historical lease classification.
Accrued Liabilities	Accrued liabilities are summarized as follows (in thousands): June 30, 2019 December 31, 2018 Compensation $ 1,046 $ 1,030 Professional fees 175 203 Interest 1,241 892 Warranty 2 2 Vacation 50 53 Preferred dividends 120 120 Stock subscription for licenses 692 692 Other accrued expenses 192 164 Total $ 3,518 $ 3,156
Revenue Recognition	The Company follows, ASC 606 Revenue from Contracts with Customers establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, Revenue based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and, the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. Revenue by product line (in thousands): Six Months Ended June 30, 2019 2018 Devices $ — $ — Disposables 2 8 Other 15 1 Warranty 2 4 Total $ 19 $ 13 Revenue by geographic location (in thousands): Six Months Ended June 30, 2019 2018 Asia $ 5 $ — Africa — 9 Europe 14 4 North America — — South America — — Total $ 19 $ 13
Significant Distributors	During the six months ended June 30, 2019, all the Company’s revenues were from two distributors and for extended warranties. Revenue from these distributors totaled approximately $19,000 for the period ended June 30, 2019. Accounts receivable were from one distributor and represents 100% of the balance for the period ended June 30, 2019. During the six months ended June 30, 2018, revenues were from three distributors, that totaled approximately $13,000.
Deferred Revenue	The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of June 30, 2019, and December 31, 2018, the Company did not have deferred revenue, respectively.
Customer Deposits	The Company follows the same principal as explained in Revenue Recognition and ASC 606. As of June 30, 2019, and December 31, 2018, the Company has received prepayments for devices and disposables and recorded this as customer deposits in the amount of $99,000 and $66,000, respectively.
Research and Development	Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.
Income Taxes	The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Management provides valuation allowances against the deferred tax assets for amounts that are not considered more likely than not to be realized. The Company is currently delinquent with its federal and applicable state tax return filings, payments and certain Federal and State Unemployment Tax filings. Some of the federal income tax returns are currently under examination by the U.S. Internal Revenue Service (“IRS”). The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company is currently in process of setting up a payment arrangement for its delinquent state income taxes with the State of Georgia and the returns are currently under review by state authorities. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At December 31, 2018, the Company has approximately $77.2 million of net operating losses. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. Corporate tax rates in the U.S. have decreased from 34% to 21%.
Uncertain Tax Positions	The Company assesses each income tax position is assessed using a two-step process. A determination is first made as to whether it is more likely than not that the income tax position will be sustained, based upon technical merits, upon examination by the taxing authorities. If the income tax position is expected to meet the more likely than not criteria, the benefit recorded in the financial statements equals the largest amount that is greater than 50% likely to be realized upon its ultimate settlement. At June 30, 2019 and December 31, 2018, there were no uncertain tax positions.
Warrants	The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants issued to non-employees based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model.
Stock Based Compensation	The Company records compensation expense related to options granted to employees and non-employees based on the fair value of the award. Compensation cost is recorded as earned for all unvested stock options outstanding at the beginning of the first year based upon the grant date fair value estimates, and for compensation cost for all share-based payments granted or modified subsequently based on fair value estimates. For the six months ended June 30, 2019 and 2018 share-based compensation for options attributable to employees, non-employees, officers and Board members were approximately $8,000 and $27,000. These amounts have been included in the Company’s statements of operations. Compensation costs for stock options which vest over time are recognized over the vesting period. As of June 30, 2019, the Company did not have any unrecognized compensation costs related to granted stock options that will be recognized.
Beneficial Conversion Features of Convertible Securities	Conversion options that are not bifurcated as a derivative pursuant to ASC 815 and not accounted for as a separate equity component under the cash conversion guidance are evaluated to determine whether they are beneficial to the investor at inception (a beneficial conversion feature) or may become beneficial in the future due to potential adjustments. The beneficial conversion feature guidance in ASC 470-20 applies to convertible stock as well as convertible debt which are outside the scope of ASC 815. A beneficial conversion feature is defined as a nondetachable conversion feature that is in the money at the commitment date. The beneficial conversion feature guidance requires recognition of the conversion option’s in-the-money portion, the intrinsic value of the option, in equity, with an offsetting reduction to the carrying amount of the instrument. The resulting discount is amortized as a dividend over either the life of the instrument, if a stated maturity date exists, or to the earliest conversion date, if there is no stated maturity date. If the earliest conversion date is immediately upon issuance, the dividend must be recognized at inception. When there is a subsequent change to the conversion ratio based on a future occurrence, the new conversion price may trigger the recognition of an additional beneficial conversion feature on occurrence.
Derivatives	The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.

2. SIGNIFICANT ACCOUNTING POL_3

2. SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Inventory valuation	June 30, December 31, 2019 2018 Raw materials $ 781 $ 783 Work in process 81 81 Finished goods 17 17 Inventory reserve (831 ) (767 ) Total $ 48 $ 114
Property and equipment	June 30, December 31, 2019 2018 Equipment $ 1,349 $ 1,378 Software 740 740 Furniture and fixtures 124 124 Leasehold Improvement 180 199 2,393 2,441 Less accumulated depreciation and amortization (2,393 ) (2,420 ) Total $ — $ 21
Accrued liabilities	June 30, 2019 December 31, 2018 Compensation $ 1,046 $ 1,030 Professional fees 175 203 Interest 1,241 892 Warranty 2 2 Vacation 50 53 Preferred dividends 120 120 Stock subscription for licenses 692 692 Other accrued expenses 192 164 Total $ 3,518 $ 3,156
Disaggregation of revenue	Revenue by product line (in thousands): Six Months Ended June 30, 2019 2018 Devices $ — $ — Disposables 2 8 Other 15 1 Warranty 2 4 Total $ 19 $ 13 Revenue by geographic location (in thousands): Six Months Ended June 30, 2019 2018 Asia $ 5 $ — Africa — 9 Europe 14 4 North America — — South America — — Total $ 19 $ 13

3. FAIR VALUE OF FINANCIAL IN_2

3. FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Schedule fo fair value for liabilities measured on a recurring basis	Fair Value at June 30, 2019 Level 1 Level 2 Level 3 Total Warrants issued in connection with Distributor Debt $ — $ — $ (114 ) $ (114 ) Warrants issued in connection with Senior Secured Debt (6,293 ) (6,293 ) Warrants issued in connection with Short-Term Loans — — (71 ) (71 ) Total long-term liabilities at fair value $ — $ — $ (6,478 ) $ (6,478 ) Fair Value at December 31, 2018 Level 1 Level 2 Level 3 Total Warrants issued in connection with Distributor Debt $ — $ — $ (114 ) $ (114 ) Warrants issued in connection with Senior Secured Debt — — (4,614 ) (4,614 ) Total long-term liabilities at fair value $ — $ — $ (4,728 ) $ (4,728 )
Summary of changes to Level 3 instruments	Distributor Debt Short-Term Loans Senior Secured Debt Total Balance, December 31, 2018 $ (114 ) $ — $ (4,614 ) $ (4,728 ) Warrants issued during the period — (71 ) — (71 ) Change in fair value during the period — — (1,679 ) (1,679 ) Balance, June 30, 2019 $ (114 ) $ (71 ) $ (6,293 ) $ (6,478 )

4. STOCKHOLDERS' DEFICIT (Table

4. STOCKHOLDERS' DEFICIT (Tables)	6 Months Ended
	Jun. 30, 2019
STOCKHOLDERS' DEFICIT:
Common stock issued	Balance at December 31, 2018 2,669,348 Issued in 2019 650,138 Balance at June 30, 2019 3,319,486
Outstanding warrants	Warrants (Underlying Shares) Outstanding, January 1, 2019 23,551,857 Issuances 14,650,000 Canceled / Expired (10 ) Exercised - Outstanding, June 30, 2019 38,201,847
Shares reserved for warrants	Warrants Exercise Price Expiration Date 13 (1) $60,000.00 per share June 14, 2021 3 (4) $24,320,000.00 per share September 10, 2019 1 (5) $29,491,840.00 per share September 27, 2019 4 (6) $18,003,200.00 per share December 2, 2019 2 (7) $5,760,000.00 per share December 2, 2020 2 (8) $7,040,000.00 per share December 2, 2020 1 (9) $7,603,200.00 per share June 29, 2020 13 (9) $512,000.00 per share September 21, 2020 24 (10) $512,000.00 per share June 29, 2020 12 (11) $512,000.00 per share September 4, 2020 1 (12) $7,603,200.00 per share September 4, 2020 1 (13) $512,000.00 per share October 23, 2020 1 (14) $7,603,200.00 per share October 23, 2020 35,937,500 (15) $0.04 per share June 14, 2021 1,725,000 (16) $0.04 per share February 21, 2021 22 (17) $11,137.28 per share June 6, 2021 250 (18) $0.04 per share February 13, 2022 25 (19) $144.00 per share May 16, 2022 688 (20) $15.20 per share November 16, 2020 250 (21) $15.20 per share December 28, 2020 75 (22) $16.08 per share January 10, 2021 4,262 (23) $0.04 per share March 19, 2021 1,875 (24) $16.08 per share March 20, 2021 63 (25) $48.00 per share April 30, 2021 125 (26) $48.00 per share May 17, 2021 125 (27) $48.00 per share May 25, 2021 500 (28) $48.00 per share June 1, 2021 1,875 (29) $200.00 per share August 22, 2021 625 (30) $200.00 per share September 18, 2021 1,250 (31) $1.12 per share October 23, 2021 19 (32) $0.64 per share November 20, 2021 375 (33) $0.32 per share December 5, 2021 100 (34) $0.16 per share December 19, 2021 188 (35) $0.24 per share December 23, 2021 14 (36) $0.24 per share December 27, 2021 313 (37) $0.24 per share January 7, 2021 188 (38) $0.21 per share January 17, 2021 438 (39) $0.16 per share January 30, 2021 625 (40) $0.16 per share February 15, 2021 325,000 (41) $0.1837 per share April 4, 2022 200,000 (42) $0.16 per share April 25, 2022 38,201,847* * Footnote 10 - CONVERTIBLE DEBT IN DEFAULT (1) Issued in June 2015 in exchange for warrants originally issued as part of a May 2013 private placement. (4) Issued as part of a September 2014 Regulation S offering. (5) Issued to a placement agent in conjunction with a 2014 public offering. (6) Issued in June 2015 in exchange for warrants originally issued as part of a 2014 public offering. (7) Issued as part of a March 2015 private placement. (8) Issued to a placement agent in conjunction with a June 2015 private placement. (9) Issued as part of a June 2015 private placement. (10) Issued as part of a June 2015 private placement. (11) Issued as part of a June 2015 private placement. (12) Issued to a placement agent in conjunction with a June 2015 private placement. (13) Issued as part of a June 2015 private placement. (14) Issued to a placement agent in conjunction with a June 2015 private placement. (15) Issued as part of a February 2016 private placement. (16) Issued to a placement agent in conjunction with a February 2016 private placement. (17) (18) Issued pursuant to a strategic license agreement. Issued as part of a February 2017 private placement. (19) Issued as part of a May 2017 private placement. (20) Issued to investors for a loan in November 2017. (21) Issued to investors for a loan in December 2017. (22) Issued to investors for a loan in January 2018. (23) Issued to investors for a loan in March 2018. (24) Issued to investors for a loan in March 2018. (25) Issued to investors for a loan in April 2018. (26) Issued to investors for a loan in May 2018. (27) Issued to investors for a loan in May 2018. (28) Issued to investors for a loan in June 2018 (29) Issued to investors for a loan in August 2018 (30) Issued to investors for a loan in September 2018 (31) Issued to investors for a loan in October 2018 (32) Issued to investors for a loan in November 2018 (33) Issued to investors for a loan in December 2018 (34) Issued to investors for a loan in December 2018 (35) Issued to investors for a loan in December 2018 (36) Issued to investors for a loan in December 2018 (37) Issued to investors for a loan in January 2019 (38) Issued to investors for a loan in January 2019 (39) Issued to investors for a loan in January 2019 (40) Issued to investors for a loan in February 2019 (41) Issued to investors for a loan in April 2019 (42) Issued to investors for a loan in April 2019

7. COMMITMENTS AND CONTINGENC_2

7. COMMITMENTS AND CONTINGENCIES (Tables)	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Future minimum rental payments under non-cancellable operating leases	Year Amount 2019 59 2020 120 2021 30 Total 209 Less: Interest 34 Present value of lease liability 175

8. NOTES PAYABLE (Tables)

8. NOTES PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2019
Notes Payable [Abstract]
Forgiveness of debt	For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange $ 661 Amount forgiven during the quarter ended September 30, 2018 (454 ) Promissory note dated September 4, 2018 $ 207 Interest accrued through June 30, 2019 10 Balance outstanding at June 30, 2019 $ 217 For Dr. Cartwright: Salary $ 337 Bonus 675 Interest on compensation 59 Loans to Company 528 Interest on loans 22 Total outstanding prior to exchange $ 1,621 Amount forgiven during the quarter ended September 30, 2018 (1,302 ) Promissory note dated September 4, 2018 $ 319 Interest accrued through June 30, 2019 16 Balance outstanding at June 30, 2019 $ 335
Notes payable in default, including related parties	June 30, 2019 December 31, 2018 Dr. Imhoff $ 199 $ 199 Dr. Cartwright 2 2 Ms. Rosenstock 50 50 Mr. Fowler 26 26 Mr. Mermelstein 226 211 GHS 15 15 GPB 17 17 Aquarius 108 108 Mr. Blumberg 70 70 Mr. James 2 2 Notes payable in default, including related parties $ 715 $ 700
Short-term notes payable, including related parties	June 30, 2019 December 31, 2018 Dr. Imhoff $ 143 $ 135 Dr. Cartwright 14 144 Dr. Faupel 1 123 Ms. Maloof 25 25 Mr. Case 150 150 Mr. Mamula 15 — Mr. Gould 100 50 K2 (Shenghuo) 177 177 Everest 18 — Premium Finance (insurance) — 50 Mr. Blumberg 191 45 Mr. Grimm 30 — Short-term notes payable, including related parties $ 864 $ 899

9. SHORT-TERM CONVERTIBLE DEBT

9. SHORT-TERM CONVERTIBLE DEBT (Tables)	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Convertible notes payable	June 30, 2019 December 31, 2018 Shenghuo $ 468 $ 432 Eagle 58 3 Adar 58 — Auctus 65 — Debt discount and issuance costs to be amortized (33 ) (10 ) Debt discount related to beneficial conversion (96 ) (45 ) Convertible notes payable, including related parties $ 520 $ 380

10. CONVERTIBLE DEBT IN DEFAU_2

10. CONVERTIBLE DEBT IN DEFAULT (Tables)	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Convertible notes in default	June 30, 2019 December 31, 2018 GPB $ 2,177 $ 2,198 GHS 367 364 Auctus 338 223 Debt Discount to be amortized — (7 ) Convertible notes in default $ 2,882 $ 2,778

11. INCOME (LOSS) PER COMMON _2

11. INCOME (LOSS) PER COMMON SHARE (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Earnings per share	In thousands Six months ended June 30, 2019 2018 Net (loss) income $ (2,878 ) $ 4,404 Basic weighted average number of shares outstanding 3,319 179 Net (loss) income per share (basic) $ (0.87 ) $ 24.60 Diluted weighted average number of shares outstanding 3,319 2,999 Net (loss) income per share (diluted) $ (0.87 ) $ 1.47 Dilutive equity instruments (number of equivalent units): Stock options — — Preferred stock — 368 Convertible debt 38,786 1,704 Warrants 30,235 748 Total Dilutive instruments 69,021 2,820

1. ORGANIZATION, BACKGROUND, _2

1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Common stock, issued	3,319		3,319		2,669
Common stock, outstanding	3,319		3,319		2,669
Working capital	$ (11,600)		$ (11,600)
Accumulated deficit	(140,512)		(140,512)		$ (137,634)
Net loss	(2,663)	$ 3,420	(2,878)	$ 4,501
Stockholders' deficit	$ (18,585)		$ (18,585)		$ (15,824)

2. SIGNIFICANT ACCOUNTING POL_4

2. SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Raw materials	$ 781	$ 783
Work in process	81	81
Finished goods	17	17
Inventory reserve	(831)	(767)
Total	$ 48	$ 114

2. SIGNIFICANT ACCOUNTING POL_5

2. SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Property and equipment	$ 2,393	$ 2,441
Less accumulated depreciation	(2,393)	(2,420)
Total	0	21
Equipment
Property and equipment	1,349	1,378
Software
Property and equipment	740	740
Furniture and Fixtures
Property and equipment	124	124
Leasehold Improvement
Property and equipment	$ 180	$ 199

2. SIGNIFICANT ACCOUNTING POL_6

2. SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Compensation	$ 1,046	$ 1,030
Professional fees	175	203
Interest	1,241	892
Warranty	2	2
Vacation	50	53
Preferred dividends	120	120
Stock subscription for licenses	692	692
Other accrued expenses	192	164
Total	$ 3,518	$ 3,156

2. SIGNIFICANT ACCOUNTING POL_7

2. SIGNIFICANT ACCOUNTING POLICIES (Details 3) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue	$ 1	$ 8	$ 19	$ 13
Asia
Revenue			5	0
Africa
Revenue			0	9
Europe
Revenue			14	4
North America
Revenue			0	0
South America
Revenue			0	0
Devices
Revenue			0	0
Disposables
Revenue			2	8
Other
Revenue			15	1
Warranty
Revenue			$ 2	$ 4

2. SIGNIFICANT ACCOUNTING POL_8

2. SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Accounting Policies [Abstract]
Patent costs	$ 10	$ 7
Lease asset-right	175		$ 0
Deferred revenue	0		0
Customer deposits	99		$ 66
Share-based compensation	8	$ 27
Unrecognized compensation costs	$ 0

3. FAIR VALUE OF FINANCIAL IN_3

3. FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Warrants	$ (6,478)	$ (4,728)
Warrants Distributor Debt
Warrants	(114)	(114)
Warrants Senior Secured Debt
Warrants	(6,293)	(4,614)
Warrants Short-Term Loans
Warrants	(71)
Level 1
Warrants	0	0
Level 1 | Warrants Distributor Debt
Warrants	0	0
Level 1 | Warrants Senior Secured Debt
Warrants	0	0
Level 1 | Warrants Short-Term Loans
Warrants	0
Level 2
Warrants	0	0
Level 2 | Warrants Distributor Debt
Warrants	0	0
Level 2 | Warrants Senior Secured Debt
Warrants	0	0
Level 2 | Warrants Short-Term Loans
Warrants	0
Level 3
Warrants	(6,478)	(4,728)
Level 3 | Warrants Distributor Debt
Warrants	(114)	(114)
Level 3 | Warrants Senior Secured Debt
Warrants	(6,293)	$ (4,614)
Level 3 | Warrants Short-Term Loans
Warrants	$ (71)

3. FAIR VALUE OF FINANCIAL IN_4

3. FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) - Level 3 $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Beginning balance	$ (4,728)
Warrants issued during the period	(71)
Change in fair value during the period	(1,679)
Ending balance	(6,478)
Distributor Debt
Beginning balance	(114)
Warrants issued during the period	0
Change in fair value during the period	0
Ending balance	(114)
Short-Term Loan
Beginning balance	0
Warrants issued during the period	(71)
Change in fair value during the period	0
Ending balance	(71)
Senior Secured Debt
Beginning balance	(4,614)
Warrants issued during the period	0
Change in fair value during the period	(1,679)
Ending balance	$ (6,293)

4. STOCKHOLDERS' DEFICIT (Detai

4. STOCKHOLDERS' DEFICIT (Details)	6 Months Ended
	Jun. 30, 2019shares
STOCKHOLDERS' DEFICIT:
Convertible debt conversions	650,138
Beginning balance	2,669,348
Issued in 2019	650,138
Ending balance	3,319,486

4. STOCKHOLDERS' DEFICIT (Det_2

4. STOCKHOLDERS' DEFICIT (Details 1)	6 Months Ended
	Jun. 30, 2019shares
Outstanding, ending	38,201,847	[1]
Warrants
Outstanding, beginning	23,551,857
Issuances	14,650,000
Canceled / Expired	(10)
Exercised	0
Outstanding, ending	38,201,847
[1]	However, please refer to Footnote 10 - CONVERTIBLE DEBT IN DEFAULT in the paragraph: Debt Restructuring for more information regarding our warrants.

4. STOCKHOLDERS' DEFICIT (Det_3

4. STOCKHOLDERS' DEFICIT (Details 2)	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Warrants outstanding	38,201,847	[1]
Warrants 1
Warrants outstanding	13
Warrants exercise price | $ / shares	$ 60,000
Expiration date	June 14, 2021
Warrants 2
Warrants outstanding	3
Warrants exercise price | $ / shares	$ 24,320,000
Expiration date	September 10, 2019
Warrants 3
Warrants outstanding	1
Warrants exercise price | $ / shares	$ 29,491,840
Expiration date	September 27, 2019
Warrants 4
Warrants outstanding	4
Warrants exercise price | $ / shares	$ 18,003,200
Expiration date	December 2, 2019
Warrants 5
Warrants outstanding	2
Warrants exercise price | $ / shares	$ 5,760,000
Expiration date	December 2, 2020
Warrants 6
Warrants outstanding	2
Warrants exercise price | $ / shares	$ 7,040,000
Expiration date	December 2, 2020
Warrants 7
Warrants outstanding	1
Warrants exercise price | $ / shares	$ 7,603,200
Expiration date	June 29, 2020
Warrants 8
Warrants outstanding	13
Warrants exercise price | $ / shares	$ 512,000
Expiration date	September 21, 2020
Warrant 9
Warrants outstanding	24
Warrants exercise price | $ / shares	$ 512,000
Expiration date	June 29, 2020
Warrant 10
Warrants outstanding	12
Warrants exercise price | $ / shares	$ 512,000
Expiration date	September 4, 2020
Warrant 11
Warrants outstanding	1
Warrants exercise price | $ / shares	$ 7,603,200
Expiration date	September 4, 2020
Warrants 12
Warrants outstanding	1
Warrants exercise price | $ / shares	$ 512,000
Expiration date	October 23, 2020
Warrants 13
Warrants outstanding	1
Warrants exercise price | $ / shares	$ 7,603,200
Expiration date	October 23, 2020
Warrants 14
Warrants outstanding	35,937,500
Warrants exercise price | $ / shares	$ 0.04
Expiration date	June 14, 2021
Warrants 15
Warrants outstanding	1,725,000
Warrants exercise price | $ / shares	$ 0.04
Expiration date	February 21, 2021
Warrants 16
Warrants outstanding	22
Warrants exercise price | $ / shares	$ 11,137.28
Expiration date	June 6, 2021
Warrants 17
Warrants outstanding	250
Warrants exercise price | $ / shares	$ 0.04
Expiration date	February 13, 2022
Warrants 18
Warrants outstanding	25
Warrants exercise price | $ / shares	$ 144
Expiration date	May 16, 2022
Warrants 19
Warrants outstanding	688
Warrants exercise price | $ / shares	$ 15.20
Expiration date	November 16, 2020
Warrants 20
Warrants outstanding	250
Warrants exercise price | $ / shares	$ 15.20
Expiration date	December 28, 2020
Warrants 21
Warrants outstanding	75
Warrants exercise price | $ / shares	$ 16.08
Expiration date	January 10, 2021
Warrants 22
Warrants outstanding	4,262
Warrants exercise price | $ / shares	$ 0.04
Expiration date	March 19, 2021
Warrants 23
Warrants outstanding	1,875
Warrants exercise price | $ / shares	$ 16.08
Expiration date	March 20, 2021
Warrants 24
Warrants outstanding	63
Warrants exercise price | $ / shares	$ 48
Expiration date	April 30, 2021
Warrants 25
Warrants outstanding	125
Warrants exercise price | $ / shares	$ 48
Expiration date	May 17, 2021
Warrants 26
Warrants outstanding	125
Warrants exercise price | $ / shares	$ 48
Expiration date	May 25, 2021
Warrants 27
Warrants outstanding	500
Warrants exercise price | $ / shares	$ 48
Expiration date	June 1, 2021
Warrants 28
Warrants outstanding	1,875
Warrants exercise price | $ / shares	$ 200
Expiration date	August 22, 2021
Warrants 29
Warrants outstanding	625
Warrants exercise price | $ / shares	$ 200
Expiration date	September 18, 2021
Warrants 30
Warrants outstanding	1,250
Warrants exercise price | $ / shares	$ 1.12
Expiration date	October 23, 2021
Warrants 31
Warrants outstanding	19
Warrants exercise price | $ / shares	$ 0.64
Expiration date	November 20, 2021
Warrants 32
Warrants outstanding	375
Warrants exercise price | $ / shares	$ 0.32
Expiration date	December 5, 2021
Warrants 33
Warrants outstanding	100
Warrants exercise price | $ / shares	$ 0.16
Expiration date	December 19, 2021
Warrants 34
Warrants outstanding	188
Warrants exercise price | $ / shares	$ 0.24
Expiration date	December 23, 2021
Warrants 35
Warrants outstanding	14
Warrants exercise price | $ / shares	$ 0.24
Expiration date	December 27, 2021
Warrants 36
Warrants outstanding	313
Warrants exercise price | $ / shares	$ 0.24
Expiration date	January 7, 2021
Warrants 37
Warrants outstanding	188
Warrants exercise price | $ / shares	$ 0.21
Expiration date	January 17, 2021
Warrants 38
Warrants outstanding	438
Warrants exercise price | $ / shares	$ 0.16
Expiration date	January 30, 2021
Warrants 39
Warrants outstanding	625
Warrants exercise price | $ / shares	$ 0.16
Expiration date	February 15, 2021
Warrants 40
Warrants outstanding	325,000
Warrants exercise price | $ / shares	$ 0.18
Expiration date	April 4, 2022
Warrants 41
Warrants outstanding	200,000
Warrants exercise price | $ / shares	$ 0.16
Expiration date	April 25, 2022
[1]	However, please refer to Footnote 10 - CONVERTIBLE DEBT IN DEFAULT in the paragraph: Debt Restructuring for more information regarding our warrants.

7. COMMITMENTS AND CONTINGENC_3

7. COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Jun. 30, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 59
2020	120
2021	30
Total payments	209
Less: imputed interest	34
Total	$ 175

8. NOTES PAYABLE (Details)

8. NOTES PAYABLE (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Bonus	$ 1,046	$ 1,030
Vacation	50	$ 53
Dr. Faupel
Salary	134
Bonus	20
Vacation	95
Interest on compensation	67
Loans to Company	196
Interest on loans	149
Total outstanding prior to exchange	661
Amount forgiven	(454)
Promissory note	207
Interest accrued	10
Promissory note, net	217
Dr. Cartwright
Salary	337
Bonus	675
Interest on compensation	59
Loans to Company	528
Interest on loans	22
Total outstanding prior to exchange	1,621
Amount forgiven	(1,302)
Promissory note	319
Interest accrued	16
Promissory note, net	$ 335

8. NOTES PAYABLE (Details 1)

8. NOTES PAYABLE (Details 1) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Notes payable in default, including related parties	$ 715	$ 700
Dr. Imhoff
Notes payable in default, including related parties	199	199
Dr. Cartwright
Notes payable in default, including related parties	2	2
Ms. Rosenstock
Notes payable in default, including related parties	50	50
Mr. Fowler
Notes payable in default, including related parties	26	26
Mr. Mermelstein
Notes payable in default, including related parties	226	211
GHS
Notes payable in default, including related parties	15	15
GPB
Notes payable in default, including related parties	17	17
Aquarius
Notes payable in default, including related parties	108	108
Mr. Blumberg
Notes payable in default, including related parties	70	70
Mr. James
Notes payable in default, including related parties	$ 2	$ 2

8. NOTES PAYABLE (Details 2)

8. NOTES PAYABLE (Details 2) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Short-term notes payable, including related parties	$ 864	$ 899
Dr. Imhoff
Short-term notes payable, including related parties	143	135
Dr. Cartwright
Short-term notes payable, including related parties	14	144
Dr. Faupel
Short-term notes payable, including related parties	1	123
Mr. Maloof
Short-term notes payable, including related parties	25	25
Mr. Case
Short-term notes payable, including related parties	150	150
Mr. Mamula
Short-term notes payable, including related parties	15	0
Mr. Gould
Short-term notes payable, including related parties	100	50
K2
Short-term notes payable, including related parties	177	177
Everest
Short-term notes payable, including related parties	18	0
Premium Finance
Short-term notes payable, including related parties	0	50
Mr. Blumberg
Short-term notes payable, including related parties	191	45
Mr. Grimm
Short-term notes payable, including related parties	$ 30	$ 0

9. SHORT-TERM CONVERTIBLE DEB_2

9. SHORT-TERM CONVERTIBLE DEBT (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Convertible notes payable	$ 520	$ 380
Shenghuo
Convertible notes payable	468	432
Eagle
Convertible notes payable	58	3
Adar
Convertible notes payable	58	0
Auctus
Convertible notes payable	65	0
Debt Credit Amortized
Convertible notes payable	(33)	(10)
Debt Discount Related to Beneficial Conversion
Convertible notes payable	$ (96)	$ (45)

10. CONVERTIBLE DEBT IN DEFAU_3

10. CONVERTIBLE DEBT IN DEFAULT (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Convertible notes in default	$ 2,882	$ 2,778
GPB
Convertible notes in default	2,177	2,198
GHS
Convertible notes in default	367	364
Auctus
Convertible notes in default	338	223
Debt Discount to be Amortized
Convertible notes in default	$ 0	$ (7)

11. INCOME (LOSS) PER COMMON _3

11. INCOME (LOSS) PER COMMON SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net (loss) income	$ (2,654)	$ 3,378	$ (2,878)	$ 4,404
Basic weighted average number of shares outstanding	3,284	246	3,319	179
Net (loss) income per share (basic)	$ (0.81)	$ 13.73	$ (0.87)	$ 24.6
Diluted weighted average number of shares outstanding	3,284	2,716	3,319	2,999
Net (loss) income per share (diluted)	$ (0.81)	$ 1.24	$ (0.87)	$ 1.47
Dilutive equity instruments (number of equivalent units)			69,021	2,820
Stock Options
Dilutive equity instruments (number of equivalent units)			0	0
Preferred Stock
Dilutive equity instruments (number of equivalent units)			0	368
Convertible Debt
Dilutive equity instruments (number of equivalent units)			38,786	1,704
Warrants
Dilutive equity instruments (number of equivalent units)			30,235	748